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The surprising presence of P. vivax in West Africa and their ability to infect a Duffy negative 
population is one more threat to public health. In order to contribute to malaria elimination 
efforts, there is a need to investigate the origin and characteristics of P. vivax population isolates 
in Northern Mali. Next Generation Sequence Analysis (NGSA) can help us understand parasite 
genetic characteristics although low parasite density is a challenge for whole genome 
sequencing (WGS).  In the present work, we investigated if selective whole genome 
amplification (sWGA) can enrich P. vivax DNA extracted from Rapid Diagnostic Tests (RDTs) 
for Whole Genome Sequencing. We also investigated the origin and the susceptibility to 
antimalarial drugs of the strains isolated in Northern Mali. 
Methods: 
Parasite DNA was extracted from 267 RDTs using the QIAamp DNA mini kit, then nested PCR 
and 7 samples were positive for P. vivax. After sWGA, the whole genomes were sequenced 
using the Illumina platform. Next Generation Sequences Analysis was done followed by 
population differentiation analyses. Twenty-two additional P. vivax whole genomes from other 
parts of the World were downloaded from the European Nucleotide Archive for further 
Neighbour Joining analysis. 
Results: 
The sequences extracted from RDTs showed high contamination with human DNA (80%). 
From the parasite DNA, in total 69529 SNPs were found in the seven P. vivax strains of 
Northern Mali. The most significant p-values per SNP were carried by the chromosomes 2, 3, 
4, 5, 12, 13 and 14. With regard to variant effects, the Transition/Transversion ratio was 1.1. 
The density of variants with a high effect was 1.62%. There was no mutation associated with 
antimalarial drugs resistance on pvcrt-o or pvmdr-1 genes. Pairwise differentiation suggests a 
high degree of relatedness between P. vivax strains isolated in Northern Mali. The Neighbours-
Joining analysis shows clearly that strains from Mali cluster together and are genetically distinct 
from those from Mauritania, which shares a border with Mali. The strains isolated in Northern 
Mali are genetically closer to those from Madagascar, India and Latina America. 
Conclusion: 
We did not identify mutations associated to the resistance to antimalarial drugs in pvcrt-o and 
pvmdr-1 genes. This study confirms that P. vivax strains genetically distinct from those of 
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Mauritania are circulating in Mali. Finally, we conclude that SWGA is a feasible approach for 
P. vivax DNA enrichment for WGS despite the high proportion of human contamination. 
 










































1. Introduction: General informations on malaria and Next 
Generation Sequencing (NGS) 
 
1.1. General introduction  
 
The malaria parasite was identified for the first time in 1880 by Charles Louis Alphonse 
Laveran. Dr Laveran was a French army surgeon stationed in Constantine, Algeria. For his 
discovery, Alphonse received the Nobel Prize in 1907 (Center for Disease Control and 
Prevention (CDC) 2017).  
Malaria is a major public health problem. An infectious bite of a female of Anopheles mosquito 
is responsible for transmitting the disease, though the transmission can rarely also occur through 
transfusion of infected blood (Merriam-Webster 2015). Though also rare, it is possible that a 
woman can infect her foetus during pregnancy or delivery (Malhotra et al. 2006). 
Among anopheles species, Anopheles gambiae, Anopheles arabiensis and Anopheles funestus 
are the primary vectors transmitting malaria in sub-Saharan Africa (Mzilahowa et al. 2012; 
Sinka et al. 2012). 
Six species of Plasmodium are known to be responsible for malaria: Plasmodium falciparum, 
Plasmodium vivax, Plasmodium ovale (P.o. curtisi and P.o. wallikeri), Plasmodium malariae 
and Plasmodium knowlesi (Medicines for Malaria Venture (MMV) 2016). Among these six 
species P. falciparum is responsible for the majority of malaria deaths (Medicines for Malaria 
Venture (MMV) 2016). P. vivax  is the most widely distributed, causing approximately half of 
all clinical cases of malaria outside of Africa (World Health Organisation(WHO) 2016c). P. 
vivax is the predominant malaria parasite american continent (64%) following by the Eastern 
Mediterranean regions (40%) and South-East Asia (30%). More than the half of P. vivax 
malaria cases occur in the WHO South-East Asia Region(World Health Organisation(WHO) 
2017d). In 1948, the presence of P. vivax was reported in Mauritania (Mint lekweiry et al. 
2012), a country sharing a border with Mali. Recently, publications showed the high prevalence 
of P. vivax malaria in Nouakchott, Mauritania (Ba et al. 2016; M. S. Ould Ahmedou Salem et 
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al. 2015; Ouldabdallahi Moukah et al. 2016). P. vivax malaria has also been reported in East 
African countries like Ethiopia, Eritrea and Sudan (Talha et al. 2015). 
Malaria is a poverty linked disease, malaria-related mortality rates are highest in low income 
countries where the highest burden is in rural areas with financial constraints (World Health 
Organisation(WHO) 2013). In endemic areas, malaria is responsible for about a 1.3% reduction 
in economic growth (Sachs and Malaney 2002). 
          Despite the fact that malaria is an evitable and curable disease, in 2016 there were 
approximately 40.6 million malaria cases and about 18,700 malaria deaths, most of them 
occurring in Sub-Saharan Africa (World Health Organisation(WHO) 2017e). Some population 
groups like children under 5 years of age, pregnant women, non-immune migrants, travellers 
and patients with HIV/AIDS are more vulnerable to malaria, and developing severe disease, 
than others (World Health Organisation(WHO) 2016a). 
 
1.2. Malaria parasites life cycle 
 
The malaria parasite life cycle involves two types of hosts (Figure 1): humans and female 
Anopheles mosquitoes. It can proliferate in different cell types while circumvening its clearance 
by the host through immune system (Greenwood et al. 2008). 
During a blood meal, the female Anopheles mosquito inoculates sporozoites into the human 
blood stream. As shown in Figure 1, after inoculation in human, sporozoites are rapidly taken 
up by the liver cells. They undergo several stages: 
- Liver stage: The duration of the hepatic stage differs according to the parasite species.  
It is shorter for P. falciparum, ~6 days. With P. vivax the duration of the hepatic stage 
is ~8 days with the possibility of slow hepatic schizogonic multiplication (hypnozoites). 
This stage is ~9 days with P. ovale, with the possibility of hypnozoites, while for P. 
malaria, the hepatic stage duration is ~15 days (Yaro Jean-Baptiste Bibié; oral 
communication). Only P. vivax and P. ovale can remain dormant in the hepatocytes for 
months or several years (Medecine for Malaria Venture 2017). The merozoites are 
released into the bloodstream after the rupture of liver cells, and then they rapidly invade 
the red blood cells. 
- Blood stage: At this stage trophozoites mature into schizonts. The rupture of schizonts 
releases merozoites. Some parasites differentiate into gametocytes (sexual erythrocytic 
stages). It is at the blood stage that the clinical manifestations of the disease appear. 
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During the blood meal, an Anopheles mosquito ingests the gametocytes (male and 
female). When gametocytes fertilize and multiply in the mosquito it is known as the 
sporogonic cycle. The zygotes then become ookinetes, the ookinetes and the zygotes 
are the only diploid form of the parasite.  Ookinetes invade the midgut wall of the 
mosquito where they develop into oocysts. Mature sporozoites exit the oocysts and 
make their way to the mosquito's salivary glands, where the future inoculation to 
humans perpetuates the malaria life cycle. P. malariae is known to have the possibility 
to persist asymptomatically in the blood for decades (Collins and Jeffery 2007). 
 
 
Figure 1: Life cycle of malaria parasites (Source: https://www.malariasite.com/life-cycle/;  
accessed 4th December 2017) 
 
1.3. Particularity of Plasmodium vivax life cycle 
 
As with the other Plasmodium species, after inoculation into the human body by female 
anopheles mosquitoes, sporozoites reach the hepatocytes and start the exoerythrocytic stage. 
Once in hepatocytes, P. vivax sporozoites can either enter in schizogonia which release 
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merozoites into the bloodstream after thousands of mitotic replications in individual 
hepatocytes, or instead, sporozoites can differentiate into a dormant stage called a hypnozoite, 
with can be activated after several months or years (Krotoski 1985). 
During the erythrocytic stages merozoites predominantly invade immature red blood 
cells, reticulocytes (Sturm 2006). Then, reticulocytes become enlarged and more deformed 
(Suwanarusk et al. 2004). In addition to producing specific proteins known as Schüfnner’s dots 
(Barnwell et al. 1990), some P. vivax parasites can differentiate into mature gametocytes. The 
Schüfnner’s dots appear as profuse speckling in Giemsa-stained blood smears. 
 
Figure 2: Plasmodium vivax life cycle (source: Mueller et al., 2009) 
 
 
1.4. Clinical manifestations of malaria 
 
At the blood stage, parasites cause massive bursting of erythrocytes causing the accumulation 
of toxic wastes that result in malaria clinical manifestations. Toxic wastes occuring from 
erythrocyte destruction trigger the production of cytokines and other soluble factors by 
macrophages and other cells lead to fevers and others clinical presentations. Many factors such 
as patient under five year old, Long term travelling from endemic area leading to the lost of 
naturally acquired immunity, the disease transmission intensity, host and parasite genetics play 
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a role in the clinical presentation (Doolan, Dobaño, and Baird 2009; Kwiatkowski 2005; 
Reyburn et al. 2005). Malaria manifests in different forms: 
 Asymptomatic Malaria: In high transmission areas, continuous exposure to malaria 
parasites can result in partial immunity that leads to asymptomatic carriers that can act 
as potential reservoirs of parasites, or gametocyte carriages resulting in persistent 
transmission (Bousema et al. 2004). In the Sikasso Region, Southern Mali, Save the 
Children reported 80% of asymptomatic malaria amongst school age children (Save the 
Children 2016). 
 Uncomplicated Malaria: Destruction of erythrocytes leads to fever and flu-like 
symptoms, such as: chills, headache, muscle aches, tiredness, loss of appetite, 
abdominal pain, nausea, vomiting, diarrhoea, etc. These initial symptoms are non-
specific to malaria. Malaria is considered uncomplicated when symptoms are present 
but there are no clinical or laboratory signs to indicate severity or vital organ 
dysfunction (Medicines for Malaria Venture 2017). 
 Severe Malaria: Almost all forms of severe malaria are caused by P. falciparum (Snow 
et al. 2005; Svenson et al. 1995) and P. vivax(Genton et al. 2008; Tjitra et al. 2008). 
Severe malaria can be manifested by cerebral malaria associated with abnormal 
behavior, impaired consciousness, seizures, coma, or other neurological abnormalities; 
severe anemia due to massive destruction of erythrocytes; low blood pressure due to 
cardiovascular collapse; hemoglobinuria due to hemolysis; acute respiratory distress 
syndrome (because of deep breathing resulting from metabolic acidosis); acute renal 
failure, etc. 
 
1.5. Plasmodium vivax malaria 
 
Even though it is less virulent than P. falciparum, P. vivax malaria can lead to severe disease 
and death (Anstey et al. 2012; Baird 2007) even if the mechanisms of severe disease are not 
clearly understood. The pyrogenic threshold in P. vivax malaria is greater than that for P. 
falciparum (Price et al. 2007). In vivax malaria, generally, parasite density is low and the 
disease severity is not characterized by high parasite density (Anstey et al. 2009).  
Unlike P. falciparum, this particular species can populate human blood with gametocytes 
in the absence of symptoms, which means that treatment of symptomatic cases does not 
necessarily help stop an outbreak (Vogel 2013). Causing no symptoms the parasite can stay 
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dormant in the liver during several days or years (hypnozoites) allowing the parasite to survive 
in more temperate zones, where mosquitoes do not bite all year round (Gething et al. 2012). It 
has been proposed that a single infection can trigger six or more relapses a year. The relapses 
can be triggered by other infectious diseases including, P. falciparum malaria (White 2011). 
Robinson LJ et al. showed that four of every five P. vivax infections are due to reactivation of 
hypnozoites during a study caried out in Papua New Guinea (Robinson et al. 2015). 
The major manifestations that can be caused by severe P. vivax are severe anaemia (Anstey 
et al. 2009, 2012; Kochar et al. 2010), acute renal injury (V B Kute et al. 2012; Vivek B. Kute 
et al. 2012), acute lung injury as well as respiratory distress (Anstey et al. 2007; Lança et al. 
2012) and even cerebral malaria (Beg et al. 2002). Previous study conducted in the Brazilian 
Amazon reported two deaths among 24 P. vivax severe cases (Lança et al. 2012). From 17 
severe P. vivax malaria cases, Lacerda et al reported 13 deaths (Lacerda et al. 2012). In 2015, 
a study revealed that the overall fatality rate due to vivax was 20-fold higher in India compared 
to Brazil (Siqueira et al. 2015). A greater risk to severe malaria has been found in inpatients for 
P. vivax compared to P. falciparum during a prospective study in Papua, Indonesia (Tjitra et al. 
2008), where an other study showed a similar case-fataly rate for inpatients with P. falciparum 
and P. vivax malaria (Poespoprodjo et al. 2009). 
 
1.6. Immunity against malaria 
 
Immunity against malaria can be naturally acquired after multiple exposures and increases with 
age. This acquisition is a process that is put in place gradually. In areas where malaria is 
endemic, individuals are continuously exposed to infections; clinical immunity to malaria is 
usually acquired in adults (Hviid 2005). The immune response of the host plays an important 
role in the immunity conferred. It has been shown that malaria immunity is age and transmission 
intensity dependent (Langhorne et al. 2008; Marsh and Kinyanjui 2006). The mechanisms by 
which immunity against malaria is acquired are not well understood. However, there is ample 
evidence to suggest that antibodies to the variant surface antigens (VSAs) of the malaria 
parasite are responsible for the progressive development of immunity (Bousema et al. 2004; 






1.7.1. Vaccine against malaria 
A large number of malaria vaccine candidates have been developed (World Health Organisation 
(WHO) 2017c). Among them the most advanced is RTS,S/AS01, a recombinant protein-based 
malaria vaccine, that has been approved for use by European regulators in July 2015 (Wikipedia 
2017). On the 24th April 2017, the World Health Organization Regional Office for Africa 
(WHO/AFRO) announced that three African countries (Ghana, Kenya, and Malawi) will 
partner with the WHO in the Malaria Vaccine Implementation Programme (MVIP) that will 
make the RTS,S vaccine available in selected areas in 2018 ((MVI) 2017). However, the RTS, 
S vaccine efficacy is limited (Malaria Vaccine Initiative 2016). 
 
1.7.2. Intermittent preventive treatment in pregnancy (IPTp) 
If malaria infection occurs during pregnancy, it can be a substantial risk for the mother, the 
foetus and the neonate (World Health Organisation (WHO) 2017). Malaria during pregnancy 
can lead to abortion, stillbirth, and low birth weight (McGready et al. 2012). Compared to non-
pregnant women, pregnant women are 3 times more likely to suffer from severe malaria, and 
have a high mortality rate from severe disease (Monif GRG 2004). To reduce maternal malaria 
episodes, anaemia, and poor delivery outcome, the WHO recommends IPTp with sulfadoxine-
pyrimethamine (World Health Organisation(WHO) 2017b). Recently a meta-analysis 
demonstrated that IPTp with 3 or more doses of sulfadoxine-pyrimethamine protects better 
against poor delivery outcomes than the standard 2-dose regimens (Kayentao et al. 2013). 
Recommendation are to observe a one month interval between doses of IPTp-SP, however, 
sulfadoxine-pyrimethamine is not indicated during the first trimester of pregnancy (World 
Health Organisation(WHO) 2017b). 
 
1.7.3. Intermittent screening and treatment (IST) 
A potential alternative to IPTp-SP, the Intermitent Screening and Treatment (IST) has been 
shown to be efficacious. In The Gambia, Mali, Burkina Faso and Ghana (countries with a low 
prevalence of resistance to sulfadoxine-pyrimethamine) IST with Artemether-Lumefantrine 
(AL) in pregnant women was found to be efficacious as well as IPTp-SP (Tagbor et al. 2015). 
The study showed that the mean haemoglobin level at the last antennal consultation was 
10.97g/dL and 10.94g/dL in women who received the IPTp-SP and ISTp-AL respectively. As 
for placental infection, it was present in 24.5% of women in the IPTp-SP group and in 24.2% 
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of women in the ISTp-AL group (OR = 0.95 [95% CI 0.81, 1.12]) (Tagbor et al. 2015). IST is 
a good alternative, particularly, for pregnant HIV positive women receiving cotrimoxazole 
prophylaxis in whom SP is contraindicated. 
 
1.7.4. Seasonal malaria chemoprevention (SMC) 
Children under 5 years of age are very vulnerable to malaria,  accounting for 70% of all malaria 
related deaths (World Health Organisation(WHO) 2016c). The intermittent administration of 
full treatment courses of antimalarial medicine to children, called SMC, is recommended in 
areas of highly seasonal malaria transmission during the transmission season. In order to 
prevent malarial episodes by maintaining therapeutic antimalarial drug concentrations in the 
blood, the WHO recommends SMC with sulfadoxine-pyrimethamine + amodiaquine in areas 
where P. falciparum is sensitive to both antimalarial drugs (World Health Organisation(WHO) 
2017c). The efficacy of SMC was demonstrated in Mali by substantially reduced prevalence 
and incidence of malaria, as well as prevalence of anaemia (Diawara et al. 2017). 
 
1.7.5. Long-lasting insecticide-treated nets (LLINs) and indoor residual spray (IRS) 
LLINs and IRS are the two tools contributing to current malaria reduction (Bhatt et al. 2015). 
Both tools are effective against the biting of malaria vectors (World Health Organisation(WHO) 
2016c). However, the effectiveness of IRS depends on malaria vectors resistance status and the 
product residual time on the wall surface (World Health Organisation(WHO) 2015b). 
 
1.8. Malaria diagnosis 
 
For effective management of malaria cases, early accurate and reliable diagnosis is essential. 
Despite the fact that early  the diagnosis is the less expensive way to facilitate treatment, the 
clinical diagnosis used alone can lead to errors due to the non-specificity of malaria signs 
(Leslie et al. 2012). WHO guidelines on malaria treatment places particular emphasis on the 
significance of the confirmation of any clinical suspicion cases (World Health 
Organisation(WHO) 2010). 
For malaria diagnosis, microscopy is the gold standard (Moody, Chiodini, and Work- 
2000), however, the identification of species other than falciparum, in particular vivax, remains 
a major challenge. Thick and thin smears are used respectively to detect infections and for 
species identification. The microscopist experience and the quality of the blood smears are very 
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important for the accuracy of microscopy diagnostic of malaria (Wongsrichanalai et al. 2007). 
Many malaria endemic regions don't have enough qualified staff and good materials to facilitate 
reliable and accurate malaria diagnosis (Ishengoma et al. 2009; Mens et al. 2007; Snounou G 
et al. 1993), leading to presumptive treatments. The Rapid Diagnostic Test (RDT) seems to be 
a good alternative, however, the sensitivity and specificity of RDT are better with P. falciparum 
infection than that with P. vivax (World Health Organisation(WHO) 2012a). 
Polymerase chain reaction (PCR) as well as serology are also known to be malaria 
diagnostic tools with good sensitivity and specificity (Mens et al. 2006, 2007; De Oliveira et 
al. 2009). 
 
1.9. Treatment of malaria 
 
Quinine has been the drug of last resort for the treatment of malaria, especially for the severe 
disease. Chloroquine was first synthesized in 1934 and has been the most widely used 
antimalarial drug. It has been the drug of choice for the treatment uncomplicated malaria and 
for chemoprophylaxis. Closely related to chloroquine, Amodiaquine is a relatively widely 
available compound. Some antibiotics such as Tetracycline and derivatives, doxycycline are 
very potent antimalarials and are used for both treatment and prophylaxis in areas where 
response to quinine has deteriorated. 
	
1.9.1. The strategies currently recommended for malaria cases management: 
	
The current tools recommended by the World Health Organization for the management of 
malaria are, on one hand, the prevention by the use of long-lasting insecticidal mosquito nets, 
indoor residual spraying for vector control, seasonal malaria chemoprevention, and intermittent 
preventive treatment for malaria in infants, and on the other hand, prompt access to diagnostic 
testing of suspected cases and the treatment of P. falciparum confirmed cases with effective 
artemisinin-based combination (ACT) therapies (World Health Organisation(WHO) 2016b).  
In 2006 Mali changed its policy of antimalarial drug of first choice because of the 
emergence of malaria parasite resistance to chloroquine. Chloroquine (CQ) was effectively 
replaced by artemisinin-based combination therapy: artemether + lumefantrine (AL) and 
artesunate + amodiaquine (AS + AQ) in 2007. The two ACTs recommended by the Malian 
National Malaria Control Programme, Artemether-Lumefantrine (AL) and Artesunate-
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Amodiaquine (AS + AQ), are known to be safe and effective(Djimdé et al. 2008; Sagara et al. 
2006). 
 
1.9.2. Treatment of P. vivax malaria  
 
Efficient antimalarial treatment in P. vivax allows the host to clear peripheral asexual parasites, 
prevent recurrent infection, and also interrupt the cycle of transmission (Baird, Maguire, and 
Price 2012). For the treatment of uncomplicated P. vivax malaria, the WHO recommends CQ  
in most endemic countries or an artemisinin combination treatment plus Primaquine (PQ) in 
G6PD positive individuals (World Health Organisation(WHO) 2014). Almost 30 years after 
chloroquine-resistant P. falciparum, chloroquine-resistant P. vivax was first reported in 1989 
(Rieckmann, Davis, and Hutton 1989). P. vivax resistance to chloroquine has not yet been 
reported in Sudan and Mauritania (M. Ould Ahmedou Salem et al. 2015; Schousboe et al. 2015), 
however Pvmdr1 mutations are emerging.  The Pvmdr1 mutated codon 976F was shown to be 
associated with treatment failure in Southeast Asia and Ethiopia (Brega et al. 2005; Golassa et 
al. 2015). In some countries like Brazil, the current treatment for P. vivax malaria is based on 
Chloroquine and Primaquine (Naing et al. 2010). Prevalence of chloroquine resistance in the 
treatment of P. vivax malaria is becoming more and more higher in Asia (Figure 3). 
Evidence on the role of pvcrt-o on the clinical response of CQ treatment has been described in 
a patient with severe malaria who had an increase in pvcrt-o gene expression 20-fold compared 
to 3 patients with P. vivax uncomplicated malaria (Fernández-Becerra et al. 2009). Also, a study 
conducted in Brazil showed that pvcrt-o expression was elevated in patients with poor response 




Figure 3: Prevalence of chloroquine resistance in the treatment of P. vivax malaria (Source: 
adapted from http://www.wwarn.org/vivax/surveyor/#0) 
 
1.10. Management of severe malaria 
 
The management of severe malaria includes emergency measures in addition to antimalarial 
drug administration (World Health Organisation(WHO) 2012b). 
The treatment recommended by WHO is artesunate at 2.4mg/kg of body weight. It should be 
given intravenously or intramuscularly immediately, 12 and 24 hours later and then once a day. 
Alternative treatment: Artemether or quinine if artesunate is not available. Artemether should 
be administrated at 3.2 mg/kg per day.  
Quinine is given at 20 mg/kg through intravenous infusion, then 10 mg/kg every 8 hours. 
 
1.11. Next Generation Sequencing (NGS) 
 
The availability of genomic sequences for pathogens can allow the extraction of strong 
epidemiologycal indicators; in addition, genetic information can also be a key to understanding 
the causes of a disease and the reactivity of pathogens to drugs. Therefore, the study of the 
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malaria parasite genome is important for disease control and elimination. Plasmodium spp. 
genetic diversity revealed within genome sequencing projects contributed to enlightened the 
parasite biology and host-parasite interaction (Hemingway et al. 2016).  Research on P. vivax 
malaria has been largely neglected leading to a general lack of knowledge about the biology of 
the plasmodial species. Currently P. vivax malaria is known to have considerable morbidity and 
mortality (Alexandre et al. 2010). Genome, transcriptome and proteome sequencing projects 
accomplished great achievements on P. vivax biology (Acharya et al. 2009, 2011; Alexandre et 
al. 2010). 
One of the challenges in sequencing P. vivax DNA extracted from RDTs is low parasite density. 
To correct this challenge, selective whole genome amplification should be an approaches 
becoming routine for parasite surveillance once the economic costs outweigh the current cost 
benefits of targeted approaches (Auburn and Barry 2017). 
The term next-generation sequencing (NGS) (Figure 4), describes a number of different modern 
sequencing technologies including: Illumina (Solexa), Roche 454, Ion torrent: Proton / PGM 
and SOLiD sequencing. These new technologies allow us to sequence DNA and RNA much 
more quickly and cheaply and as such have revolutionised the study of genomics and molecular 
biology (YourGenome 2017).  
DNA sequencing using NGS include three general steps (Atdbio 2005): 
- Library preparation: during this first step, libraries are created using random 
fragmentation of DNA either enzymatically or by sonication. DNA fragmentation is 
followed by ligation with custom linkers; 
- Amplification: during the second step, the library is amplified using clonal amplification 
methods and PCR; 
- Sequencing: finally, DNA is sequenced using one of several different approaches. 
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Figure 4: DNA sequencing steps (Source: https://www.slideshare.net/ueb52/introduction-to-
next-generation-sequencing-v2) 
 
1.12. Study justification 
One of the characteristics that distinguish Plasmodium vivax from Plasmodium falciparum is 
the development of dormant hypnozoite forms in the liver that cause subsequent infections in 
the blood called relapses (Krotoski WA 1985). The World Health Organization (WHO) 
reported that more than 30% of the world’s population is at risk of P. vivax infection. This 
parasite is mostly present in Asia and Latin America. In 2013, more than one million P. vivax 
malaria cases were recorded in four countries (Ethiopia, India, Indonesia and Pakistan) 
(Mizutani et al. 2016; World Health Organisation(WHO) 2015a). In Saharan Africa, Berber 
people, who are mostly Duffy-positive have been infected by P. vivax (Howes et al. 2015; Picot 
2006). The circulation of P. vivax in Central Africa (Cameroon), as well as its ability to infect 
Duffy-negative individuals was described previously (Mbenda, Gouado, and Das 2016; Russo 
et al. 2017).  This particular parasite has been thought to be absent from West Africa because 
of the Duffy blood group, a blood receptor considered indispensable for the invasiveness of this 
species into red blood cells. More than 90% of the population in this area are believed to be 
Duffy negative (Miller et al. 1976). However, in 2012 a report showed that 25 (28.4%) out of 
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88 samples analysed from Northern Mali contained mature stages of P. vivax, (M Bernabeu et 
al. 2012). Recently, P. vivax was found in four black, African women living near Bamako in 
Mali (Williams et al. 2016). It is not yet known where these cases originated. Hence the 
importance of studying these parasites in the global context of the malaria elimination agenda. 
The surprising appearance of P. vivax in west Africa and its ability to infect Duffy negative 
populations is one more threat to population health. Research on P. vivax malaria was neglected 
in West Africa because of the belief that it was relatively benign, it was believed that this species 
is not able to infect Duffy-negative individuals. In order to contribute to malaria control and 
elimination efforts, there is a need to investigate the genetic characteristics of these P. vivax 
isolates and the divergence in orthologues of genes conferring antimalarial drug resistance in 
P. falciparum. This is critical in understanding the potential resistance pattern of the parasite to 
these drugs in Northern Mali. Bioinformatics has the potential to help us understand parasite 
genetic characteristics. 
1.13. Hypothesis and Objectives 
 
1.13.1. Hypothesis 
We hypothesize that using selective Whole Genome Amplification, DNA extracted from Rapid 
Diagnostic tests will allow us to determine the origin of P. vivax isolated from Northern Mali. 
 
1.13.2. Objectives 
1.13.2.1. General objective 
To assess the genetic characteristics and origin of P. vivax isolates from Northern Mali. 
 
1.13.2.2. Specific objectives:  
- To determine variation levels and their effects in pvcrt-o and pvmdr-1 genes in Northern 
Mali strains. 
- To determine the genetic relationships between P. vivax field isolates collected from 
Northern Mali. 
- To determine the evolutionary relationship of the P. vivax parasites from Mali with 







2.1. Study sites 
 
The analysis used data collected from a previous cross-sectional epidemiological study 
conducted in October 2015 in the region of Kidal in Northern Mali. As indicated in the Figure 
5, Kidal is located at ~1,564 km in North-East of Bamako. 
 
Figure 5: Map of Mali showing study sites 
(Source: adapted from https://simplemaps.com/resources/svg-ml) 
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In Mali, malaria is the primary cause of morbidity and mortality, in particular amongst the 
vulnerable youth (Ministère de la Santé du Mali 2007; PMI 2016). Malaria is endemic in the 
central and southern regions of the country and epidemic in the northern regions (Mouhamadou 
GUEYE, Bourama FANE 2015). In 2012, the prevalence of malaria reported by the 
Demographic and Health Survey was 52% amongst Malian children under five years of age 
(PMI 2016). In Mali one in twenty children die before their fifth birthday because of malaria 
(IRIN 2007). In 2015, 5272 cases of malaria were reported for the region of Kidal in Mali 
compared to 2267 cases in 2014, an increase of 3005 cases (Ministère de la Santé et de 
l’Hygiène Publique 2015). 
 
2.2. Study description 
 
Following the emergence of malaria cases in the region of Kidal, the Ministry of Health and 
Public Hygiene and WHO organized an emergency meeting in Bamako. During this meeting, 
the MRTC proposed, in addition to an epidemiological cross-sectional study, a response to this 
emergency with the seasonal malaria chemoprevention (SMC) strategy, indoor residual 
spraying (IRS) of insecticide, and management of confirmed malaria cases. Malaria rapid 
diagnosis tests were performed on the patients presenting fever or with history of fever using 
the SD BIOLINE Malaria Ag P. f test. Parasite DNA was extracted from rapid diagnosis tests 
using the QIAamp DNA mini kit (Qiagen, Valencia, CA) (Annex 19). After nested PCR 
(Snounou G et al. 1993) (Annex 19), out of 267 samples, 7 were found to be positive for P. 
vivax. DNA from these parasites were subjected to selective Whole-Genome Amplification 
(sWGA) (Cowell et al. 2017) (Annex 20) followed by NGS (Behjati and Tarpey 2013) using 
Illumina Platform at MACROGNE in Corea. 
 
2.3. Ethical considerations 
 
The samples were collected anonymously during the management of a malaria epidemic in 
northern Mali, at the request of the Ministry of Health and Public Hygiene. The analysis of the 
samples has been approved both by the ethics committee of the Faculty of Medicine, Pharmacy 
and Dentistry at the University of Sciences, Techniques and Technologies of Bamako in Mali 
and the ethics committee in the University of Cape Town (UCT), South Africa.  
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2.4. Next Generation Sequencing 
 
2.4.1. Library QC  
Using a DNA 1000 chip, the template size distribution was checked by running on an Agilent 
Technologies 2100 Bioanalyzer in the order to verify the size of PCR enriched fragments. Using 
qPCR according to the Illumina qPCR Quantification Protocol Guide, prepared libraries were 
quantified. Roche's Rapid library standard Quantification solution allowed to generate a 
standard curve of fluorescence readings. Then, the library sample concentration was calculated. 
 
As shown in table 1 all seven samples passed the Illumina library quality control. 
After performing quality control (QC) the library construction was performed. 
 
Table 1: Illumina library quality control 
Library name Library type Conc. (ng/µl) Conc. (nM) Size (bp) Result 
1 TruSeq DNA PCR Free (350) 6.74 22.06 470 Pass 
2 TruSeq DNA PCR Free (350) 6.42 21.01 470 Pass 
3 TruSeq DNA PCR Free (350) 9.29 30.41 470 Pass 
4 TruSeq DNA PCR Free (350) 4.71 15.41 470 Pass 
5 TruSeq DNA PCR Free (350) 8.17 26.75 470 Pass 
6 TruSeq DNA PCR Free (350) 5.43 17.77 470 Pass 
7 TruSeq DNA PCR Free (350) 8.86 29.00 470 Pass 
 
2.4.2. Whole genome sequencing 
The Illumina Hiseq platform was used for the whole genome sequencing using the procedure 
shown in the Figure 6.  
 
Figure 6: Sequencing Experiment Overview (Source: http://dna.macrogen.com) 
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2.4.2.1. Sample preparation 
DNA was extracted from the samples as described above. After performing quality control 
(QC), the library construction proceeded. 
2.4.2.2. Library construction 
The sequencing library was prepared by random fragmentation of the DNA or cDNA sample 
followed by 5' and 3' adapter ligation, then, adapter-ligated fragments were PCR amplified and 
gel purified. 
2.4.2.3. Sequencing 
Illumina sequencing by synthesis (SBS) technology was used for the sequencing. The result 
was highly accurate base-by-base sequencing with few errors, even within repetitive sequence 
regions and homopolymers. 
2.4.2.4. Raw data 
Sequenced data were converted into raw data using fastq.gz file format for the analysis. 
 
2.5. Data quality assessment 
 
2.5.1. Quality assessment 
The quality scores demonstrate quality and thus the usability of the data. We used fastQC for 
sequence quality assessment and considered a Phred quality score ≥ 20 as good qualities. More 
than 90% of the reads had a quality score > 20. 
 
2.5.2. Verification of contamination and filtering 
Using bowtie2-2.2.6 (Langmead and Salzberg 2012), we first mapped the P. vivax sequences 
to the human reference genome (Annex 1) in order to check for contamination with host DNA. 
Samtools (Li et al. 2009) (Version: 1.5) was used to compute the mapping rate (Annex 2). 
Thereafter, we extracted the reads that did not align with the human reference genome using 
Bam2fastq version1.1.0 (HudsonAlpha 2010)(Annex 3).  
 
2.6. Reference genomes 
 




The human reference genome was downloaded from the European Nucleotide Archive database 
(ENA at https://www.ebi.ac.uk/ena/data/view/GCA_000001405.26) in fasta format. P. vivax 
whole genome sequences from Mauritania, Madagascar, Brazil, Peru and India were also 
downloaded from the European Nucleotide Archive (ENA) 
(https://www.ebi.ac.uk/ena/data/search?query=).   
 
2.7. Sample size 
 
For this analysis, we used 7 P. vivax whole genome sequences from the region of Kidal in Mali, 
8 whole genome sequences from Mauritania, 3 from Madagascar, 3 from India, 3 from Brazil 
and 5 from Peru (see Figure 7). Thus, a total of 29 P. vivax whole genome sequences, all 
sequenced on Illumina HiSeq 2000, were used.  
 
Figure 7: World map showing the origins of the parasite sequence data (Source: adapted from 
https://commons.wikimedia.org/wiki/File:World_map_between_2003_and_2005.png) 
 
2.8. Data Analysis procedure 
 
2.8.1. Next Generation Sequencing Analysis 
We ran the following pipelines: 
- Quality Control 
- Read Alignment 
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- Variant Identification 
- Annotation 
2.8.1.1. Read Alignment 
The reads that did not align with the human reference genome were mapped onto the P. vivax 
reference genome using SMALT (http://www.sanger.ac.uk/resources/software/smalt) with 
default parameters to first extract the P. vivax reads. We evaluated the sequence conformity to 
the reference genome with Samtools (Annex 4). Next, the reads aligned with the P. vivax 
reference genome were extracted using Bam2fastq version1.1.0 (HudsonAlpha 2010)(Annex 
5) and re-aligned with the P. vivax reference genome using SMALT (Annex 6).  
 
2.8.1.2. Variant calling 
Variant calling was done using Samtools-0.1.19 following 3 steps. We first indexed the 
reference genome; next, we used samtools (Li et al. 2009) to generate a BCF file; and finally, 
using bcftools-0.1.19, the variants were filtered (Annex 7). 
Like the samples isolated from Northern Mali, all the data downloaded from the ENA were 
subjected to contamination filtering, alignment to the P. vivax reference genome and variant 
calling following the same pipeline (Annex 11, 12, 13, 14 and 15).  
 
2.8.1.3. Annotation 
An open source tool, snpEff 4.3t (build 2017-11-24 10:18) (Li et al. 2017) was used to annotate 
variants and predict the coding effects. The P. vivax genes of interest (chloroquine resistance 
transporter: pvcrt-o and multidrug resistance protein: pvmdr-1, were searched in the NCBI Gene 
database (https://www.ncbi.nlm.nih.gov/gene/).  
SnpSift version 4.3t (build 2017-11-24 10:18) was used to extract the variation positions within 
antimalarial drugs resistance genes descriptions in EnsemblProtists 
(https://protists.ensembl.org/biomart/martview/d4bb190f94368e623c0f9ea7894abfeb).   
 
2.8.2. Population differentiation 
PLINK-version 1.90b5.1(Alexander and Lange 2011) was used to generate a pca file from the 
Mali P. vivax vcf file to measure the Northern Mali P. vivax population differentiation (Annex 
8). The eigenvec file was used in R (version 3.4.2) to perform a principal component analysis 
(Annex 9) to determine the genetic distance among parasites collected in Northern Mali. 
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2.8.3. Neighbour Joining analysis 
Similar to the analysis performed on Malian samples, we performed an NGS analysis on strains 
from other countries. The BAM files were used to generate common variant calling files. Then, 
positions overlapping with the strains of Northern Mali with the highest number of reads were 
used for Neighbour Joining analysis (Annex 15). Using PLINK 1.9, ped files were generated 
from variant calling files.  The ped files were converted into fasta files (Annex 16). Using the 
MAFFT/7.305_intel16.0.1 program, we aligned the sequences (Annex 17) to determine the 
evolutionary relationships.  
A Neighbour-Joining method (Saitou and Nei 1987) was used to study the evolutionary 
history of the taxa. The evolutionary distances were computed using the Maximum Composite 
Likelihood method (Tamura, Nei, and Kumar 2004). This analysis involved 28 nucleotide 
sequences from Northern Mali, Mauritania, Madagascar, Brazil, Peru and India. All positions 
containing gaps and missing data were eliminated. The evolutionary analysis was done using 
































In order to determine the origin of the 7 P. vivax sequences isolated in Northern Mali, we first 
assessed the quality of the sequence data, processed it and did variant calling. Then we did 
pairwaise differentiation and evolutionary analysis using 22 additional existing P. vivax 
sequences from other regions of the World. 
 
3.1. Determination of the data quality 
 
3.1.1. NanoDrop reports 
The selective Whole Genome Amplification allowed DNA enrichment for WGS. Before 
amplification, the DNA quantities were almost undetectable. For the second sample, from just 
traces, the quantity increased to exceed 15 ng/µl. 
  
3.1.2. Sequence quality 
The average GC content was about 41. More than 91% of the reads had a quality control (QC) 
score above 20. The mapping of our sequences with the human reference genome showed a 













Table 2: Sample quality summary statistics 
 Total reads GC content Q20 (%) Mapping rate on human reference 
genome (%) 
Sample 1 64,319,870 41.07 91.78 70.15 
Sample 2 66,094,594 43.05 91.68 57.42 
Sample 3 57,033,898 39.19 92.53 97.34 
Sample 4 65,600,582 42.06 91.62 55.63 
Sample 5 68,643,540 39.78 92.8 95.07 
Sample 6 73,421,330 40.49 92.24 87.53 
Sample 7 65,239,736 40.24 92.32 94.21 
 
After filtering the reads that did not align with the human reference genome, for the alignment 
with the Plasmodium vivax reference genome (Table 3), the sample from TinEssako (region of 
Kidal) had the most reads mapping to P. vivax P01. 
The result illustrates that in addition to human DNA, the samples were highly contaminated 
with other organisms. 
 
Table 3: Mapping rate with P. vivax reference genome after filtering out human DNA 
 Origin Total reads unaligned with 
human reference genome 
Reads mapped to P. 
vivax reference genome 
Mapping rate 
(%) 
Sample 1 Kidal 17810776 755252 4.24 
Sample 2 Kidal 26444138 756434 2.86 
Sample 3 Kidal 159580 43340 27.16 
Sample 4 Kidal 27747574 1117428 4.03 
Sample 5 Kidal 144920 10053 6.94 
Sample 6 Anefis 7174992 333354 4.65 
Sample 7 Tin-Essako 1855108 1285572 69.30 
 
 
Despite the high contamination with human and other DNA, the remaining sequences had a 
number of reads covered by the P. vivax reference genome. When all contamination was 
removed, the re-alignment with the P. vivax reference genome showed that the sample collected 
in TinEssako had the most reads aligning with the P. vivax reference genome. The deep 
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coverage was above five for Kidal2 and Tin-Essako. Sample 5 which has lower x-coverage 
(Figure 8), and fewer than 4,000 reads, was not used for further analysis. 
 
Table 4: P. vivax DNA extracted mapping rate with P. vivax reference genome 
 Origin Total reads extracted as P. 
vivax DNA  
Reads mapped with P. 
vivax reference genome 
Mapping rate 
(%) 
Sample 1 Kidal 63654 60932 95.72 
Sample 2 Kidal 66868 64729 96.80 
Sample 3 Kidal 21300 21068 98.91 
Sample 4 Kidal 80820 77164 95.48 
Sample 5 Kidal 2886 2837 98.30 
Sample 6 Anefis 49334 47938 97.17 









3.2. Variant annotation 
 
We then did variant annotation using snpEff for the 6 samples from the Northern Mali that had 
enough reads. Table 5 shows the chromosome length, the numbers of variants as well as the 
average number of bases that separate the variants. The variants are closer to each other in 
chromosome 4 where there is a variant on average each 196 bases. The density is highest for 
chromosome 4, followed by chromosome 10 with a variant density of 206. The greatest distance 
between the variants was observed in chromosome 14. The lowest number of variants was 
observed on chromosome 1, and the highest number is on chromosome 9. 
 
Table 5: Variants number and density by chromosome. 
Chromosome Length Variants Variant density 
Chr1 830,022   2,629 315 
Chr2 755,035 3,527 214 
Chr3 1,011,127 3,083 327 
Chr4 876,622 4,459 196 
Chr5 1,370,936 3,898 351 
Chr6 1,033,388 2,715 380 
Chr7 1,497,819 4,045 370 
Chr8 1,678,596 3,886 431 
Chr9 1,923,364 7,611 252 
Chr10 1,419,739 6,868 206 
Chr11 2,067,354 4,651 444 
Chr12 3,004,884 6,445 466 
Chr13 2,031,768 4,194 484 








Genetic variation provides a way for populations to evolve in response to environmental 
changes. In our analysis, unsurprisingly, the variants with high effects have the lowest 
proportion (1.6%) (table 6-A). However, the results show a high level of missense mutation 
(almost 75%) (table 6-B). The ratio of transitions/transversions was about 1.11 (table 6-D). 
 




















With regard to the frequency of effects by type and localization (table 7), downstream (33.4%) 
and upstream (34.8%) regions of genes are carrying more than 67% of the variants. Variants 
were much more often observed on exons (14.4%) compared to introns (1.6%). Non-coding 
transcript variants were the least frequent (0.001%). 
 
















Table 8 summarizes the amino acid changes where the rows are reference amino acids. 
Phenylalanine (F) is replaced 263 times by Leucine (L), both are essential amino acids. 
Histidine (H) is replaced 143 times by Glutamine (Q), a non-essential amino acid. Isoleucine is 
highly replaced by Leucine (both are essentials). Leucine is more often replaced by 
Phenylalanine (F) and Methionine (M) by Isoleucine. The essential amino acid Threonine (T) 
is replaced 152 times by the non-essential Serine (S). Diagonals indicated using grey 
background color are synonymous mutations. 
 















3.3. Genes related to resistance against antimalarial drugs in Northern Mali 
strains 
 
The chloroquine resistance transporter (pvcrt-o) is found on Chromosome 1, and the multidrug 
resistance protein (pvmdr-1), on Chromosome 10. In total, 58 variants were found in the two 
genes from Northern Mali strains using SNPeff. In pvcrt-o we found one variant leading to a 
high effect on Chloroquine resistance associated protein (table 9). Two variations in the pvmdr-
1 gene whose one at the position 357357 have large effects on an uncharacterized protein 
(PVX_080090) (table 10). 
From the EnsemblProtists variants database, we looked for pvcrt-o and pvmdr-1gene 
orthologues with the same variants in Plasmodium falciparum 3D7. From EnsemblProtists the 
variants we observed were: rs45338627, rs45319121, rs45319122, rs45365696, rs45319123, 
rs45365697 rs45319125, rs45365699, rs45338628 and rs45319126, all were carried by 
Chromosome 10. However, none of them expressed a functional or phenotypic description.  
None of the variants observed in the gene pvcrt-o nor 65.5% (19 out of 29) of the variants 
observed on the pvmdr-1 gene have been described yet in the EnsemblProtists variants database 



















Table 9: Chloroquine resistance transporter (pvcrt-o) variants and their effects 
Chromosome Position REF ALT Type of variant Effect 
chr1     326582 T C Synonymous Low 
chr1     326764 G        C Missense        Moderate 
chr1     327016 T        C Upstream gene        Modifier 
chr1     329317 G        A Upstream gene Modifier 
chr1     330262 G        A 5′ UTR  Modifier 
chr1     330541 TAT      T 5’UTR Modifier 
chr1     330818 G        GG 5’UTR Modifier 
chr1     330857 A        C 5’UTR Modifier 
chr1     330860 T        C 5’UTR Modifier 
chr1     330862 G        C 5’UTR Modifier 
chr1     330884 T        C 5’UTR Modifier 
chr1     331359 G        A Synonymous Low 
chr1     331421 G        C Missense        Moderate 
chr1     332758 C        T Upstream gene Modifier 
chr1     333045 T        C Upstream gene Modifier 
chr1     333863 C        A Upstream gene Modifier 
chr1     333864 A        C Upstream gene Modifier 
chr1     333868 C        A Upstream gene Modifier 
chr1     335228 T        TT Upstream gene Modifier 
chr1     336610 A        C Upstream gene Modifier 
chr1     336773 T        TT Upstream gene Modifier 
chr1     336962 G        A Upstream gene Modifier 
chr1     337343 C        T,A Initiator codon Low 
chr1     338023 C        T Synonymous Low 
chr1     338133 T        C Missense        Moderate 
chr1     338140 T        C Synonymous Low 
chr1     338622 A        C Missense        Moderate 
chr1     338847 A        G Missense        Moderate 




Table 10: Multidrug resistance protein (pvmdr-1) variants and their effects 
Chromosome Position REF ALT Type of variant Effect 
chr10     356721 C        T Missense        Moderate 
chr10    357357 T        TTT Frameshift High 
chr10    357878 T        G Upstream gene Modifier 
chr10    357885 G        C Upstream gene Modifier 
chr10    357887 A        G Upstream gene Modifier 
chr10    357890 A        T Upstream gene Modifier 
chr10    357891 G        T Upstream gene Modifier 
chr10    357894 A        G Upstream gene Modifier 
chr10    357898 C        G Upstream gene Modifier 
chr10    357900 G        A Upstream gene Modifier 
chr10    357903 T        A Upstream gene Modifier 
chr10    357988 T        G Upstream gene Modifier 
chr10    358161 T        A Upstream gene Modifier 
chr10    358819 A        C 5’UTR Modifier 
chr10    359147 A        AA Frameshift High 
chr10    359988 C        T Missense        Moderate 
chr10    360536 T        G Missense        Moderate 
chr10    360602 A        G Missense        Moderate 
chr10    361889 A        G Missense        Moderate 
chr10    363144 C        T Synonymous Low 
chr10    363676 G        A Missense        Moderate 
chr10    363970 G        T Missense        Moderate 
chr10    365622 T        C Synonymous Low 
chr10    366628 C        A Upstream gene Modifier 
chr10    366718 A        T Upstream gene Modifier 
chr10    367286 G        A Upstream gene Modifier 
chr10    369415 G        GGG Upstream gene Modifier 
chr10    370450 T        G Missense        Moderate 
chr10    370990 C        T Synonymous Low 
ALT= alternate allele, REF= reference allele, UTR= Untranslated region 
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3.4. Determination of the genetic relationships between P. vivax field isolates 
collected in Northern Mali 
 
Using PLINK we investigated the genetic distance between P. vivax strains collected in the 
Kidal region. Table 11 shows the standard deviation of each component used for the prinincipal 
component analysis. The standard deviations of the components were ~0.45 for each 
component, and the proportions of variance were the same at 20%.    
 
Table 11: The importance of components 
 Comp.1 Comp.2 Comp.3  Comp.4 Comp.5 
Standard deviation 0.4472 0.4472 0.4472 0.4472 0.4472 
Proportion of Variance 0.2000 0.2000 0.2000 0.2000 0.2000 






















The principal component analysis (PCA) plot (Figure 9) shows that strains isolated from rural 
areas (Anefis and Tin-Essako) are genetically close to each other, and the strains collected in 
the Kidal district are clustering together. Only, the third strain collected in the Kidal district is 
genetically distant from the others. 
 
 









3.5. Determination of the genetic distance between P. vivax parasites from 
Northern Mali and those from other parts of the world 
The Neighbour-Joining analysis was done using P. vivax genome isolates from Northern Mali 
and other countries in Africa, Asia and Latina America. The phylogenetic tree (Figure 10) 
shows clearly that almost all strains of Northern Mali are clustering together and are genetically 
distinct from those from Mauritania. Only the strain collected at Tin-Essako is moving away 
from the Mali isolates and is not close to any other strain used in this analysis. The phylogenetic 
tree demonstrates that P. vivax strains from Mauritania are clustering alone and are genetically 
distinct from those of other parts of the world. The 3 strains from Madagascar used in this 
analysis are genetically closely related to the strains from India. The Neighbour-Joining 
analysis shows that isolates from Latina America are clustering together and genetically close 
the strains isolated from India.  
 






4.1. Study context and data quality 
 
This study was conducted in a context of emergency management why rapid diagnostic tests 
was used for malaria diagnostic. For long time, P. vivax has been thought absent from West-
Africa, due to the absence of the Duffy antigen (Maria Bernabeu et al. 2012). However, 
scientific evidence shows that human P. vivax is recognized to be from Africa (Liu et al. 2014). 
Nowadays, only one route experimentally confirmed, using the Duffy antigen, is known to be 
used by P. vivax for invading reticulocytes (Horuk et al. 1993; Miller et al. 1976). Regardless 
of its pathway for entrance into reticulocytes and geographical origin, the presence of P. vivax 
in Africa is not sufficiently explored. 
 
We have shown for the first to our knowledge that P. vivax whole genome can be recovered 
from a RDT, which is used for diagnostics. The result shows that selective whole-genome 
amplification (SWGA) is a good approach for P. vivax DNA enrichment for Whole Genome 
Sequencing. Cowell et al. demonstrated that sWGA is a robust tool for the enrichment of P. 
vivax DNA extracted from human blood samples and dried blood spots for the purpose of high-
quality WGS (Cowell et al. 2017).  
Our samples were, however significantly contaminated with the host's DNA and other 
organisms (Tables 2 and 3). This probably occured because the samples are from rapid 
diagnostic tests, and the depletion of white blood cells (WBC) was not possible before parasite 
DNA extraction. A previous study showed that, with over 80% human host DNA 
contamination, enzymatic treatment enriches P. falciparum DNA for more efficient WGS 
(Oyola et al. 2013). For our study, due to time constraints and availability of samples, we had 





4.2. Single Nucleotide Polymorphisms and Indels 
 
The coverage of Northern Mali sequences was not very deep, just over the 5x (Figure 8). 
Although the hurdle of SNP calling using low-coverage sequencing data has been recognized 
(Yu and Sun 2013), we still managed to get SNP’s called from these sequences. 
P. vivax isolates from northen Mali displayed extensive genetic variation. Mutation provides a 
way for a parasite population to evolve in response to environmental changes (Furusawa 2012).  
Northern Mali P. vivax strains have few variants with high effects but a high rate of missense 
mutation (Table 6). It is known that missense mutations can lead to non-functional proteins 
(Minde et al. 2011), and such mutations can lead to diseases in humans (Boillée, Vande Velde, 
and Cleveland 2006) or drug resistance in parasites.  
 
4.3. Antimalarial drug resistance genes 
 
Chloroquine resistance in P. falciparum was found to be strongly associated with the Pfcrt gene 
K76T mutation (Fidock et al. 2000). However, it has been described in previous publications 
that the P. vivax ortholog of Pfcrt, Pvcg10 was not  involved in chloroquine resistance in P. 
vivax (Nomura et al. 2001). 
We did not identify variants in the pvcrt-o or pvmdr-1 orthologs in P. falciparum that could 
lead to antimalarial resistance. This suggests that Chloroquine and Primaquine recommended 
in the treatment of P. vivax malaria (ALVING et al. 1953; López-Antuñano 1999) could remain 
effective against Northern Mali strains. The resistance of P. vivax to Chloroquine has not yet 
been documented in Mauritania or Sudan (M. Ould Ahmedou Salem et al. 2015; Schousboe et 
al. 2015). However, P. vivax resistance to Chloroquine has reached an alarming level in 
Indonesia, East Timor and Papua New Guinea (Baird 2009). Convincing evidence of P vivax 
resistance to chloroquine has been reported from Thailand (Phyo et al. 2011), Cambodia (Leang 
et al. 2013), Ethiopia (Yohannes et al. 2011) and South America (De Santana Filho et al. 2007). 
In somes countries like Indonesia, Malaysia and Cambodia ACT is advised for P. vivax malaria 




4.4. Genetic relationships between P. vivax field isolates collected in Northern 
Mali 
 
 Principal component analysis is a powerful method for discriminating populations that 
are genetically very close (Arora et al. 2011). In the PCA, we used 6 clinical samples among 
which, 4 were from the Kidal district, 1 from Anefis and 1 from TinEssako, from the region of 
Kidal. Anefis and TinEssako are based respectively 95 km southwest and 115 km east of the 
Kidal district. The plot in Figure 19 shows that the strains are clustering based on the sampling 
area. Only one strain from the Kidal district seemed genetically distinct from the others and 
could have been imported from another locality by a patient travelling from another village to 
the district. In a previous study, Hupalo et al. demonstrated that P. vivax genomic sequences 
cluster mostly according to their geographic origins (Hupalo et al. 2016). High genome-wide 
diversity has been found in relatively close geographic areas in P. vivax populations in the 
Americas (de Oliveira et al. 2017). It has been described in several publications that in Africa, 
local P. vivax populations are nearly as polymorphic as their P. falciparum counterparts (Chang 
et al. 2012; Mobegi et al. 2014; Prabhat Jha et al 2016). 
The phylogenetic tree (Figure 10) shows that P. vivax strains from Northern Mali, which 
are genetically close to each other, seem not to have originated from patients from the 
neighbouring country, Mauritania, while the strains from Latina America are clustering 
together. The result confirms that P. vivax parasite populations are circulating in west Africa. 
P. vivax infection was described in pregnant women on the periphery of Bamako in 2016 
(Williams et al. 2016) and recently in Duffy-negative children in Bandiagara (Niangaly et al. 
2017), in the centre of Mali. The authors suggest that it is possible that P. vivax could have been 
introduced from the Sahara desert in the north (M Bernabeu et al. 2012; Koita et al. 2012). 
Evidence of P. vivax infection in Duffy negative populations was previously described in 
Western Kenya (Ryan et al. 2006). 
Surprisingly, one strain isolated from Northern Mali, Tin-Essako, seemed to be genetically 
distinct from the other strains used in this analysis and could have a different ancestry. The 
strains from Madagascar are clustering with those of India and are genetically closer to the 
strains from India, Brazil and Peru. 
Scientific evidence shows that the origin of human P. vivax is in Africa because it arose 
from within a Plasmodium species that infects chimpanzees and gorillas (Liu et al. 2014). 
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Though previously several authors assumed that P. vivax originated from Asia (Carlton, Das, 
and Escalante 2013; Escalante et al. 2005; Mu et al. 2005). 
 Regarding the spread of the P. vivax species, we can propose the two hypothesis. 
First, the African slave trade to the Americas and Europe in the 16th century could have favoured 
the migration of Plasmodium vivax to North America, India and Asia (Figure 11). secondly, 
merchants carrying goods by boat could also have spread the P. vivax species (Figure 12). 
 





Figure 12: World map showing a plausible path of migration of P. vivax from India to 

























This study aimed to investigate the usefullness of sWGA to enrich P. vivax DNA extract from 
RDTs, the origin of the strains isolated in Northern Mali and their susceptibility to antimalarial 
drugs. 
The results obtained allow us to draw the following conclusions: 
- For low parasite density, even when the DNA is extracted from a RDT, this study 
consolidates that selective Whole Genome Amplification is a useful alternative for P. 
vivax DNA enrichment for Whole Genome Sequencing.  
- This study confirms that Plasmodium vivax strains circulating in Northern Mali are 
genetically distinct from those of Mauritania.  
- We did not identify mutations associated to the resistance to antimalarial drugs in pvcrt-
o and pvmdr-1 genes. 
 
5.2. Limitations 
We note some important limitations to this analysis. Genomic DNA was extracted from 
RDTs, which in addition to not allowing the depletion of white blood cells might have 
suffered from the known low parasite density inherent to P. vivax. Also, the sample size 
was smaller than that needed for some kinds of analyses, such as genome-wide association 
studies. A large sample size is needed to further investigate the susceptibility to 
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Annex 1: Script used to align the sequences with human reference genome 
 
#PBS -N Aligment_vivax_hum 
#PBS -q UCTlong 
#PBS -l nodes=1:ppn=32:series600 
DIR=/researchdata/fhgfs/djmmou001/moussa_data 
 
# NB, PLEASE READ THIS! 
# There is a 2:1 correspondence between RAM and cores on the 600 series. 
# You need to know how much RAM your job will consume before submitting it. 
# Please set the ppn value above to be 1/2 the GB of RAM required.  For 
# example a job needing 10GB of RAM should have ppn=5 
 
# Please leave the hostname command here for troubleshooting purposes hostname 
 
# Your science stuff goes here: 
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/human_reference.fasta $DIR/human-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/human-ref -1 $DIR/1_1.fastq -2 
$DIR/1_2.fastq -S $DIR/kidal1.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/human-ref -1 $DIR/2_1.fastq.gz -2 
$DIR/2_2.fastq.gz -S $DIR/kidal2.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/human-ref -1 $DIR/3_1.fastq.gz -2 
$DIR/3_2.fastq.gz -S $DIR/kidal3.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/human-ref -1 $DIR/4_1.fastq.gz -2 







Annex 2: Script used to compute the sequences mapping rate with human reference genome 
 
#PBS -N mapping_rate_hum 
#PBS -q UCTlong 
#PBS -l nodes=1:ppn=32:series600 
DIR=/researchdata/fhgfs/djmmou001/moussa_data/bamfiles 
 
# NB, PLEASE READ THIS! 
# There is a 2:1 correspondence between RAM and cores on the 600 series. 
# You need to know how much RAM your job will consume before submitting it. 
# Please set the ppn value above to be 1/2 the GB of RAM required.  For 
# example a job needing 10GB of RAM should have ppn=5 
 
# Please leave the hostname command here for troubleshooting purposes hostname 
 
# Your science stuff goes here: 
/opt/exp_soft/samtoools-1.3.1/samtools view -bT PvivaxP01_Genome.fasta kidal1.sam > 
kidal1.bam  
/opt/exp_soft/samtoools-1.3.1/samtools sort kidal1.bam > stdkidal1.bam 
/opt/exp_soft/samtoools-1.3.1/samtools index stdkidal1.bam 
/opt/exp_soft/samtoools-1.3.1/samtools flagstat stdkidal1.bam 
/opt/exp_soft/samtoools-1.3.1/samtools view -bT PvivaxP01_Genome.fasta kidal2.sam > 
kidal2.bam  
/opt/exp_soft/samtoools-1.3.1/samtools sort kidal2.bam > stdkidal2.bam 
/opt/exp_soft/samtoools-1.3.1/samtools index stdkidal2.bam 
/opt/exp_soft/samtoools-1.3.1/samtools flagstat stdkidal2.bam 
/opt/exp_soft/samtoools-1.3.1/samtools view -bT PvivaxP01_Genome.fasta kidal3.sam > 
kidal3.bam  
/opt/exp_soft/samtoools-1.3.1/samtools sort kidal3.bam > stdkidal3.bam 
/opt/exp_soft/samtoools-1.3.1/samtools index stdkidal3.bam 
/opt/exp_soft/samtoools-1.3.1/samtools flagstat stdkidal3.bam 
/opt/exp_soft/samtoools-1.3.1/samtools view -bT PvivaxP01_Genome.fasta kidal4.sam > 
kidal4.bam  
/opt/exp_soft/samtoools-1.3.1/samtools sort kidal4.bam > stdkidal4.bam 
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/opt/exp_soft/samtoools-1.3.1/samtools index stdkidal4.bam 
/opt/exp_soft/samtoools-1.3.1/samtools flagstat stdkidal4.bam 
/opt/exp_soft/samtoools-1.3.1/samtools view -bT PvivaxP01_Genome.fasta kidal5.sam > 
kidal5.bam  
/opt/exp_soft/samtoools-1.3.1/samtools sort kidal5.bam > stdkidal5.bam 
/opt/exp_soft/samtoools-1.3.1/samtools index stdkidal5.bam 
/opt/exp_soft/samtoools-1.3.1/samtools flagstat stdkidal5.bam 
/opt/exp_soft/samtoools-1.3.1/samtools view -bT PvivaxP01_Genome.fasta Anefis.sam > 
Anefis.bam  
/opt/exp_soft/samtoools-1.3.1/samtools sort Anefis.bam > stdAnefis.bam 
/opt/exp_soft/samtoools-1.3.1/samtools index stdAnefis.bam 
/opt/exp_soft/samtoools-1.3.1/samtools flagstat stdAnefis.bam 
/opt/exp_soft/samtoools-1.3.1/samtools view -bT PvivaxP01_Genome.fasta TinEssako.sam > 
TinEssako.bam  
/opt/exp_soft/samtoools-1.3.1/samtools sort TinEssako.bam > TinEssako.bam 
/opt/exp_soft/samtoools-1.3.1/samtools index stdTinEssako.bam 




























# Extraction of unmapped reads from bam files 
 
bam2fastq -o Anefis_filtered_R#.fastq --no-aligned Anefis.bam 
 
bam2fastq -o Kidal1_filtered_R#.fastq --no-aligned kidal1.bam 
 
bam2fastq -o Kidal2_filtered_R#.fastq --no-aligned kidal2.bam 
 
bam2fastq -o Kidal3_filtered_R#.fastq --no-aligned kidal3.bam 
 
bam2fastq -o Kidal4_filtered_R#.fastq --no-aligned kidal4.bam 
 
bam2fastq -o Kidal5_filtered_R#.fastq --no-aligned kidal5.bam 
 



































# Alignment of sequences with P. vivax reference genome using SMALT 
 
smalt index -k 14 -s 8 vivax_ref PlasmoDB-35_PvivaxP01_Genome.fasta 
 
smalt map -o Anefis_map.sam vivax_ref Anefis_filtered_R_1.fastq Anefis_filtered_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta Anefis_map.sam > 
Anefis_map.bam 
samtools sort Anefis_map.bam > Anefis_mapStd.bam 
samtools index Anefis_mapStd.bam 
samtools flagstat Anefis_mapStd.bam 
 
smalt map -o Kidal1_map.sam vivax_ref Kidal1_filtered_R_1.fastq 
Kidal1_filtered_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta Kidal1_map.sam > 
Kidal1_map.bam 
samtools sort Kidal1_map.bam > Kidal1_mapStd.bam 
samtools index Kidal1_mapStd.bam 
samtools flagstat Kidal1_mapStd.bam 
 
smalt map -o Kidal2_map.sam vivax_ref Kidal2_filtered_R_1.fastq 
Kidal2_filtered_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta Kidal2_map.sam > 
Kidal2_map.bam 
samtools sort Kidal2_map.bam > Kidal2_mapStd.bam 
samtools index Kidal2_mapStd.bam 
samtools flagstat Kidal2_mapStd.bam 
 
smalt map -o Kidal3_map.sam vivax_ref Kidal3_filtered_R_1.fastq 
Kidal3_filtered_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta Kidal3_map.sam > 
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Kidal3_map.bam 
samtools sort Kidal3_map.bam > Kidal3_mapStd.bam 
samtools index Kidal3_mapStd.bam 
samtools flagstat Kidal3_mapStd.bam 
 
smalt map -o Kidal4_map.sam vivax_ref Kidal4_filtered_R_1.fastq 
Kidal4_filtered_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta Kidal4_map.sam > 
Kidal4_map.bam 
samtools sort Kidal4_map.bam > Kidal4_mapStd.bam 
samtools index Kidal4_mapStd.bam 
samtools flagstat Kidal4_mapStd.bam 
 
smalt map -o Kidal5_map.sam vivax_ref Kidal5_filtered_R_1.fastq 
Kidal5_filtered_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta Kidal5_map.sam > 
Kidal5_map.bam 
samtools sort Kidal5_map.bam > Kidal5_mapStd.bam 
samtools index Kidal5_mapStd.bam 
samtools flagstat Kidal5_mapStd.bam 
 
smalt map -o TinEssako_map.sam vivax_ref TinEssako_filtered_R_1.fastq 
TinEssako_filtered_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta TinEssako_map.sam > 
TinEssako_map.bam 
samtools sort TinEssako_map.bam > TinEssako_mapStd.bam 
samtools index TinEssako_mapStd.bam 











# Extraction of mapped reads from bam file 
 
# And then, extract the reads aligned with P. vivax 
 
bam2fastq -o Anefis_map-vivax_R#.fastq --no-unaligned Anefis_map.bam 
 
bam2fastq -o Kidal1_map-vivax_R#.fastq --no-unaligned Kidal1_map.bam 
 
bam2fastq -o Kidal2_map-vivax_R#.fastq --no-unaligned Kidal2_map.bam 
 
bam2fastq -o Kidal3_map-vivax_R#.fastq --no-unaligned Kidal3_map.bam 
 
bam2fastq -o Kidal4_map-vivax_R#.fastq --no-unaligned Kidal4_map.bam 
 
bam2fastq -o Kidal5_map-vivax_R#.fastq --no-unaligned Kidal5_map.bam 
 























# Alignment of sequences with P. vivax reference genome using SMALT 
  
smalt map -o Anefis_smalt.sam smalt_vivax Anefis_map-vivax_R_1.fastq Anefis_map-
vivax_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta Anefis_smalt.sam > 
Anefis_smalt.bam 
samtools sort Anefis_smalt.bam > Anefis_Stdsmalt.bam 
samtools index Anefis_Stdsmalt.bam 
samtools flagstat Anefis_Stdsmalt.bam 
 
smalt map -o Kidal1_smalt.sam smalt_vivax Kidal1_map-vivax_R_1.fastq Kidal1_map-
vivax_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta Kidal1_smalt.sam > 
Kidal1_smalt.bam 
samtools sort Kidal1_smalt.bam > Kidal1_Stdsmalt.bam 
samtools index Kidal1_Stdsmalt.bam 
samtools flagstat Kidal1_Stdsmalt.bam 
 
smalt map -o Kidal2_smalt.sam smalt_vivax Kidal2_map-vivax_R_1.fastq Kidal2_map-
vivax_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta Kidal2_smalt.sam > 
Kidal2_smalt.bam 
samtools sort Kidal2_smalt.bam > Kidal2_Stdsmalt.bam 
samtools index Kidal2_Stdsmalt.bam 
samtools flagstat Kidal2_Stdsmalt.bam 
 
smalt map -o Kidal3_smalt.sam smalt_vivax Kidal3_map-vivax_R_1.fastq Kidal3_map-
vivax_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta Kidal3_smalt.sam > 
Kidal3_smalt.bam 
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samtools sort Kidal3_smalt.bam > Kidal3_Stdsmalt.bam 
samtools index Kidal3_Stdsmalt.bam 
samtools flagstat Kidal3_Stdsmalt.bam 
 
smalt map -o Kidal4_smalt.sam smalt_vivax Kidal4_map-vivax_R_1.fastq Kidal4_map-
vivax_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta Kidal4_smalt.sam > 
Kidal4_smalt.bam 
samtools sort Kidal4_smalt.bam > Kidal4_Stdsmalt.bam 
samtools index Kidal4_Stdsmalt.bam 
samtools flagstat Kidal4_Stdsmalt.bam 
 
smalt map -o Kidal5_smalt.sam smalt_vivax Kidal5_map-vivax_R_1.fastq Kidal5_map-
vivax_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta Kidal5_smalt.sam > 
Kidal5_smalt.bam 
samtools sort Kidal5_smalt.bam > Kidal5_Stdsmalt.bam 
samtools index Kidal5_Stdsmalt.bam 
samtools flagstat Kidal5_Stdsmalt.bam 
 
smalt map -o TinEssako_smalt.sam smalt_vivax TinEssako_map-vivax_R_1.fastq 
TinEssako_map-vivax_R_2.fastq 
samtools view -bT PlasmoDB-35_PvivaxP01_Genome.fasta TinEssako_smalt.sam > 
TinEssako_smalt.bam 
samtools sort TinEssako_smalt.bam > TinEssako_Stdsmalt.bam 
samtools index TinEssako_Stdsmalt.bam 












# Variant calling 
 
samtools index PlasmoDB-35_PvivaxP01_Genome.fasta 
samtools index Anefis_Stdsmalt.bam 
samtools index Kidal1_Stdsmalt.bam 
samtools index Kidal2_Stdsmalt.bam 
samtools index Kidal3_Stdsmalt.bam 
samtools index Kidal4_Stdsmalt.bam 
samtools index TinEssako_Stdsmalt.bam 
 
samtools mpileup -u -f PlasmoDB-35_PvivaxP01_Genome.fasta Anefis_Stdsmalt.bam  
Kidal1_Stdsmalt.bam Kidal2_Stdsmalt.bam Kidal3_Stdsmalt.bam Kidal4_Stdsmalt.bam 
TinEssako_Stdsmalt.bam > mali_vivax.bcf 





















# Creation of ped bed fam files using plink 
/Users/mdjimde/Documents/plink_mac/plink --vcf mali_vivax.vcf --snps-only --biallelic-only 
strict --allow-extra-chr --keep-allele-order --make-bed --out vivax2 
 
# Association study 
/Users/mdjimde/Documents/plink_mac/plink --bfile Mali --assoc --allow-extra-chr --allow-
no-sex --out Mali_assoc 
 
# Generating pca file 




























# PCA 2 Dimensions 
 
# Work directory setting 
setwd("~/Desktop/Folders/MSc_UCT/P_vivax/Seq_Data/Mali_vivax/") 
 
# We can visualise files present in the work directory 
dir() 
 
# Creating the pdf file for result storing 
pdf("PCAplot_vivax.pdf", width=5, height=3) 
 
# PCA computing 
pca_model <- read.table("snp_mali_update.pca.evec") 
 
names(pca_model) <- c("SampleID", "PC1", "PC2", "PC3","PC4",  
                      "PC5", "vivax_Strain") 
 












Annex 10: Script used to filter contamination from vivax sequences from Mauritania, align with 
vivax reference genome and variant calling  
 
#PBS -N Aligment_2_Variants 
#PBS -q UCTlong 
#PBS -l nodes=1:ppn=32:series600 
DIR=/researchdata/fhgfs/djmmou001/Vivax_data 
 
# NB, PLEASE READ THIS! 
# There is a 2:1 correspondence between RAM and cores on the 600 series. 
# You need to know how much RAM your job will consume before submitting it. 
# Please set the ppn value above to be 1/2 the GB of RAM required.  For 
# example a job needing 10GB of RAM should have ppn=5 
 
# Please leave the hostname command here for troubleshooting purposes hostname 
 
# Your science stuff goes here: 
# Your science stuff goes here: 
# First step: alignment with human reference genome 
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/entry.fasta $DIR/Human-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332408_1.fastq.gz 
-2 $DIR/SRR332408_2.fastq.gz -S $DIR/Maurit-H$ 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332409_1.fastq.gz 
-2 $DIR/SRR332409_2.fastq.gz -S $DIR/Maurit-H$ 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332410_1.fastq.gz 
-2 $DIR/SRR332410_2.fastq.gz -S $DIR/Maurit-H$ 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332411_1.fastq.gz 
-2 $DIR/SRR332411_2.fastq.gz -S $DIR/Maurit-H$ 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332412_1.fastq.gz 
-2 $DIR/SRR332412_2.fastq.gz -S $DIR/Maurit-H$ 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332413_1.fastq.gz 
-2 $DIR/SRR332413_2.fastq.gz -S $DIR/Maurit-H$ 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332414_1.fastq.gz 
-2 $DIR/SRR332414_2.fastq.gz -S $DIR/Maurit-H$ 
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/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332415_1.fastq.gz 
-2 $DIR/SRR332415_2.fastq.gz -S $DIR/Maurit-H$ 
 
# Second step: generate bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Maurit-
Hum_SRR332408.sam -o $DIR/Maurit-Hum_SRR332408.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Maurit-
Hum_SRR332409.sam -o $DIR/Maurit-Hum_SRR332409.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Maurit-
Hum_SRR332410.sam -o $DIR/Maurit-Hum_SRR332410.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Maurit-
Hum_SRR332411.sam -o $DIR/Maurit-Hum_SRR332411.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Maurit-
Hum_SRR332412.sam -o $DIR/Maurit-Hum_SRR332412.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Maurit-
Hum_SRR332413.sam -o $DIR/Maurit-Hum_SRR332413.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Maurit-
Hum_SRR332414.sam -o $DIR/Maurit-Hum_SRR332414.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Maurit-
Hum_SRR332415.sam -o $DIR/Maurit-Hum_SRR332415.bam 
 
# Third step: filtering human DNA 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt_filtered08_R#.fastq --no-aligned 
$DIR/Maurit-Hum_SRR332408.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt_filtered09_R#.fastq --no-aligned 
$DIR/Maurit-Hum_SRR332409.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt_filtered10_R#.fastq --no-aligned 
$DIR/Maurit-Hum_SRR332410.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt_filtered11_R#.fastq --no-aligned 
$DIR/Maurit-Hum_SRR332411.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt_filtered12_R#.fastq --no-aligned 
$DIR/Maurit-Hum_SRR332412.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt_filtered13_R#.fastq --no-aligned 
$DIR/Maurit-Hum_SRR332413.bam 
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/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt_filtered14_R#.fastq --no-aligned 
$DIR/Maurit-Hum_SRR332414.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt_filtered15_R#.fastq --no-aligned 
$DIR/Maurit-Hum_SRR332415.bam 
 
# Fourth step: align with vivax reference genome the read unaligned with human genome 
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/PlasmoDB-35_PvivaxP01_Genome.fasta 
$DIR/vivax-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Maurt_filtered08_R_1.fastq -2 $DIR/Maurt_filtered08_R_2.fastq -S 
$DIR/Maurt_filtered08.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Maurt_filtered09_R_1.fastq -2 $DIR/Maurt_filtered09_R_2.fastq -S 
$DIR/Maurt_filtered09.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Maurt_filtered10_R_1.fastq -2 $DIR/Maurt_filtered10_R_2.fastq -S 
$DIR/Maurt_filtered10.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Maurt_filtered11_R_1.fastq -2 $DIR/Maurt_filtered11_R_2.fastq -S 
$DIR/Maurt_filtered11.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Maurt_filtered12_R_1.fastq -2 $DIR/Maurt_filtered12_R_2.fastq -S 
$DIR/Maurt_filtered12.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Maurt_filtered13_R_1.fastq -2 $DIR/Maurt_filtered13_R_2.fastq -S 
$DIR/Maurt_filtered13.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Maurt_filtered14_R_1.fastq -2 $DIR/Maurt_filtered14_R_2.fastq -S 
$DIR/Maurt_filtered14.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Maurt_filtered15_R_1.fastq -2 $DIR/Maurt_filtered15_R_2.fastq -S 
$DIR/Maurt_filtered15.sam 
 
# Fifth step: generate filtered bam files 
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/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurt_filtered08.sam -o $DIR/Maurt_filtered08.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurt_filtered09.sam -o $DIR/Maurt_filtered09.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurt_filtered10.sam -o $DIR/Maurt_filtered10.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurt_filtered11.sam -o $DIR/Maurt_filtered11.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurt_filtered12.sam -o $DIR/Maurt_filtered12.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurt_filtered13.sam -o $DIR/Maurt_filtered13.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurt_filtered14.sam -o $DIR/Maurt_filtered14.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurt_filtered15.sam -o $DIR/Maurt_filtered15.bam 
 
# Sixth step: extract reads mapping with vivax reference genome 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt-vivax08_R#.fastq --no-unaligned 
$DIR/Maurt_filtered08.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt-vivax09_R#.fastq --no-unaligned 
$DIR/Maurt_filtered09.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt-vivax10_R#.fastq --no-unaligned 
$DIR/Maurt_filtered10.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt-vivax11_R#.fastq --no-unaligned 
$DIR/Maurt_filtered11.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt-vivax12_R#.fastq --no-unaligned 
$DIR/Maurt_filtered12.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt-vivax13_R#.fastq --no-unaligned 
$DIR/Maurt_filtered13.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Maurt-vivax14_R#.fastq --no-unaligned 
$DIR/Maurt_filtered14.bam 
 




/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Maurt-
vivax08_R_1.fastq -2 $DIR/Maurt-vivax08_R_2.fastq -S $DIR/Maurit08.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Maurt-
vivax09_R_1.fastq -2 $DIR/Maurt-vivax09_R_2.fastq -S $DIR/Maurit09.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Maurt-
vivax10_R_1.fastq -2 $DIR/Maurt-vivax10_R_2.fastq -S $DIR/Maurit10.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Maurt-
vivax11_R_1.fastq -2 $DIR/Maurt-vivax11_R_2.fastq -S $DIR/Maurit11.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Maurt-
vivax12_R_1.fastq -2 $DIR/Maurt-vivax12_R_2.fastq -S $DIR/Maurit12.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Maurt-
vivax13_R_1.fastq -2 $DIR/Maurt-vivax13_R_2.fastq -S $DIR/Maurit13.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Maurt-
vivax14_R_1.fastq -2 $DIR/Maurt-vivax14_R_2.fastq -S $DIR/Maurit14.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Maurt-
vivax15_R_1.fastq -2 $DIR/Maurt-vivax15_R_2.fastq -S $DIR/Maurit15.sam 
 
# Eighth step: generate filtered bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurit08.sam -o $DIR/Maurit08.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurit09.sam -o $DIR/Maurit09.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurit10.sam -o $DIR/Maurit10.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurit11.sam -o $DIR/Maurit11.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurit12.sam -o $DIR/Maurit12.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurit13.sam -o $DIR/Maurit13.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurit14.sam -o $DIR/Maurit14.bam 
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/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Maurit15.sam -o $DIR/Maurit15.bam 
 
# Ninth step: Sort the bam files 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Maurit08.bam $DIR/Maurit08_Std 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Maurit09.bam $DIR/Maurit09_Std 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Maurit10.bam $DIR/Maurit10_Std 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Maurit11.bam $DIR/Maurit11_Std 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Maurit12.bam $DIR/Maurit12_Std 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Maurit13.bam $DIR/Maurit13_Std 
























Annex 11: Script used to filter contamination from Madagascar sequences, align with vivax 
reference genome and variant calling 
 
#PBS -N Aligment_2_Variants 
#PBS -q UCTlong 
#PBS -l nodes=1:ppn=32:series600 
DIR=/researchdata/fhgfs/djmmou001/Vivax_data 
 
# NB, PLEASE READ THIS! 
# There is a 2:1 correspondence between RAM and cores on the 600 series. 
# You need to know how much RAM your job will consume before submitting it. 
# Please set the ppn value above to be 1/2 the GB of RAM required.  For 
# example a job needing 10GB of RAM should have ppn=5 
 
# Please leave the hostname command here for troubleshooting purposes hostname 
 
# Your science stuff goes here: 
# Your science stuff goes here: 
# First step: alignment with human reference genome 
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/entry.fasta $DIR/Human-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR570031_1.fastq.gz 
-2 $DIR/SRR570031_2.fastq.gz -S $DIR/Madag-Hum_SRR570031.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR572651_1.fastq.gz 
-2 $DIR/SRR572651_2.fastq.gz -S $DIR/Madag-Hum_SRR572651.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR828416_1.fastq.gz 
-2 $DIR/SRR828416_2.fastq.gz -S $DIR/Madag-Hum_SRR828416.sam 
 
# Second step: generate bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Madag-
Hum_SRR570031.sam -o $DIR/Madag-Hum_SRR570031.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Madag-
Hum_SRR572651.sam -o $DIR/Madag-Hum_SRR572651.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Madag-
Hum_SRR828416.sam -o $DIR/Madag-Hum_SRR828416.bam 
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# Third step: filtering human DNA 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Madag_filtered31_R#.fastq --no-aligned 
$DIR/Madag-Hum_SRR570031.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Madag_filtered51_R#.fastq --no-aligned 
$DIR/Madag-Hum_SRR572651.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Madag_filtered16_R#.fastq --no-aligned 
$DIR/Madag-Hum_SRR828416.bam 
 
# Fourth step: align with vivax reference genome the read unaligned with human genome 
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/PlasmoDB-35_PvivaxP01_Genome.fasta 
$DIR/vivax-ref 
$DIR/Madag_filtered16_R_1.fastq -2 $DIR/Madag_filtered16_R_2.fastq -S 
$DIR/Madag16_filt.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Madag_filtered31_R_1.fastq -2 $DIR/Madag_filtered31_R_2.fastq -S 
$DIR/Madag31_filt.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Madag_filtered51_R_1.fastq -2 $DIR/Madag_filtered51_R_2.fastq -S 
$DIR/Madag51_filt.sam 
 
# Fifth step: generate filtered bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Madag16_filt.sam -o $DIR/Madag16_filt.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Madag31_filt.sam -o $DIR/Madag31_filt.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Madag51_filt.sam -o $DIR/Madag51_filt.bam 
 
# Sixth step: extract reads mapping with vivax reference genome 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Madag16-vivax_R#.fastq --no-unaligned 
$DIR/Madag16_filt.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Madag31-vivax_R#.fastq --no-unaligned 
$DIR/Madag31_filt.bam 
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/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Madag51-vivax_R#.fastq --no-unaligned 
$DIR/Madag51_filt.bam 
 
# Seventh step: align again with vivax reference genome  
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/PlasmoDB-35_PvivaxP01_Genome.fasta 
$DIR/vivax-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Madag16-
vivax_R_1.fastq -2 $DIR/Madag16-vivax_R_2.fastq -S $DIR/Madagascar16.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Madag31-
vivax_R_1.fastq -2 $DIR/Madag31-vivax_R_2.fastq -S $DIR/Madagascar31.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Madag51-
vivax_R_1.fastq -2 $DIR/Madag51-vivax_R_2.fastq -S $DIR/Madagascar51.sam 
 
# Eighth step: generate filtered bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Madagascar16.sam -o $DIR/Madag16.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Madagascar31.sam -o $DIR/Madag31.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Madagascar51.sam -o $DIR/Madag51.bam 
 
# Ninth step: Sort the bam files 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Madag16.bam $DIR/Madagascar16_sorted 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Madag31.bam $DIR/Madagascar31_sorted 











Annex 12: Script used to filter contamination from Peru sequences, align with vivax reference 
genome and variant calling 
 
#PBS -N Aligment_2_Variants 
#PBS -q UCTlong 
#PBS -l nodes=1:ppn=32:series600 
DIR=/researchdata/fhgfs/djmmou001/Vivax_data 
 
# NB, PLEASE READ THIS! 
# There is a 2:1 correspondence between RAM and cores on the 600 series. 
# You need to know how much RAM your job will consume before submitting it. 
# Please set the ppn value above to be 1/2 the GB of RAM required.  For 
# example a job needing 10GB of RAM should have ppn=5 
 
# Please leave the hostname command here for troubleshooting purposes hostname 
 
# Your science stuff goes here: 
# Your science stuff goes here: 
# First step: alignment with human reference genome 
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/entry.fasta $DIR/Human-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 
$DIR/SRR1568202_1.fastq.gz -2 $DIR/SRR1568202_2.fastq.gz -S $DIR/Peru-
Hum_SRR1568202.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 
$DIR/SRR1562606_1.fastq.gz -2 $DIR/SRR1562606_2.fastq.gz -S $DIR/Peru-
Hum_SRR1562606.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 
$DIR/SRR1562614_1.fastq.gz -2 $DIR/SRR1562614_2.fastq.gz -S $DIR/Peru-
Hum_SRR1562614.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 
$DIR/SRR1568216_1.fastq.gz -2 $DIR/SRR1568216_2.fastq.gz -S $DIR/Peru-
Hum_SRR1568216.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 




# Second step: generate bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Peru-
Hum_SRR1568202.sam -o $DIR/Peru-Hum_SRR1568202.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Peru-
Hum_SRR1562606.sam -o $DIR/Peru-Hum_SRR1562606.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Peru-
Hum_SRR1562614.sam -o $DIR/Peru-Hum_SRR1562614.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Peru-
Hum_SRR1568216.sam -o $DIR/Peru-Hum_SRR1568216.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/Peru-
Hum_SRR1562624.sam -o $DIR/Peru-Hum_SRR1562624.bam 
 
# Third step: filtering human DNA 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Peru02_filtered_R#.fastq --no-aligned 
$DIR/Peru-Hum_SRR1568202.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Peru06_filtered_R#.fastq --no-aligned 
$DIR/Peru-Hum_SRR1562606.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Peru14_filtered_R#.fastq --no-aligned 
$DIR/Peru-Hum_SRR1562614.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Peru16_filtered_R#.fastq --no-aligned 
$DIR/Peru-Hum_SRR1568216.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Peru24_filtered_R#.fastq --no-aligned 
$DIR/Peru-Hum_SRR1562624.bam 
 
# Fourth step: align with vivax reference genome the read unaligned with human genome 
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/PlasmoDB-35_PvivaxP01_Genome.fasta 
$DIR/vivax-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Peru02_filtered_R_1.fastq -2 $DIR/Peru02_filtered_R_2.fastq -S $DIR/Peru02_filt.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Peru06_filtered_R_1.fastq -2 $DIR/Peru06_filtered_R_2.fastq -S $DIR/Peru06_filt.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
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$DIR/Peru14_filtered_R_1.fastq -2 $DIR/Peru14_filtered_R_2.fastq -S $DIR/Peru14_filt.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Peru16_filtered_R_1.fastq -2 $DIR/Peru16_filtered_R_2.fastq -S $DIR/Peru16_filt.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Peru24_filtered_R_1.fastq -2 $DIR/Peru24_filtered_R_2.fastq -S $DIR/Peru24_filt.sam 
 
# Fifth step: generate filtered bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Peru02_filt.sam -o $DIR/Peru02_filt.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Peru06_filt.sam -o $DIR/Peru06_filt.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Peru14_filt.sam -o $DIR/Peru14_filt.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Peru16_filt.sam -o $DIR/Peru16_filt.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Peru24_filt.sam -o $DIR/Peru24_filt.bam 
 
# Sixth step: extract reads mapping with vivax reference genome 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Peru02-vivax_R#.fastq --no-unaligned 
$DIR/Peru02_filt.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Peru06-vivax_R#.fastq --no-unaligned 
$DIR/Peru06_filt.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Peru14-vivax_R#.fastq --no-unaligned 
$DIR/Peru14_filt.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Peru16-vivax_R#.fastq --no-unaligned 
$DIR/Peru16_filt.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Peru24-vivax_R#.fastq --no-unaligned 
$DIR/Peru24_filt.bam 
 
# Seventh step: align again with vivax reference genome  
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/PlasmoDB-35_PvivaxP01_Genome.fasta 
$DIR/vivax-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Peru02-vivax_R_1.fastq 
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-2 $DIR/Peru02-vivax_R_2.fastq -S $DIR/Peru02.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Peru06-vivax_R_1.fastq 
-2 $DIR/Peru06-vivax_R_2.fastq -S $DIR/Peru06.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Peru14-vivax_R_1.fastq 
-2 $DIR/Peru14-vivax_R_2.fastq -S $DIR/Peru14.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Peru16-vivax_R_1.fastq 
-2 $DIR/Peru16-vivax_R_2.fastq -S $DIR/Peru16.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Peru24-vivax_R_1.fastq 
-2 $DIR/Peru24-vivax_R_2.fastq -S $DIR/Peru24.sam 
 
# Eighth step: generate filtered bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Peru02.sam -o $DIR/Peru02.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Peru06.sam -o $DIR/Peru06.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Peru14.sam -o $DIR/Peru14.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Peru16.sam -o $DIR/Peru16.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Peru24.sam -o $DIR/Peru24.bam 
 
# Ninth step: Sort the bam files 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Peru02.bam $DIR/Peru02_sorted 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Peru06.bam $DIR/Peru06_sorted 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Peru14.bam $DIR/Peru14_sorted 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Peru16.bam $DIR/Peru16_sorted 








Annex 13: Script used to filter contamination from India sequences, align with vivax reference 
genome and variant calling 
 
#PBS -N Aligment_2_Variants 
#PBS -q UCTlong 
#PBS -l nodes=1:ppn=32:series600 
DIR=/researchdata/fhgfs/djmmou001/Vivax_data 
 
# NB, PLEASE READ THIS! 
# There is a 2:1 correspondence between RAM and cores on the 600 series. 
# You need to know how much RAM your job will consume before submitting it. 
# Please set the ppn value above to be 1/2 the GB of RAM required.  For 
# example a job needing 10GB of RAM should have ppn=5 
 
# Please leave the hostname command here for troubleshooting purposes hostname 
 
# Your science stuff goes here: 
# Your science stuff goes here: 
# First step: alignment with human reference genome 
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/entry.fasta $DIR/Human-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332913_1.fastq.gz 
-2 $DIR/SRR332913_2.fastq.gz -S $DIR/India-Hum_SRR332913.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332914_1.fastq.gz 
-2 $DIR/SRR332914_2.fastq.gz -S $DIR/India-Hum_SRR332914.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332915_1.fastq.gz 
-2 $DIR/SRR332915_2.fastq.gz -S $DIR/India-Hum_SRR332915.sam 
 
# Second step: generate bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/India-
Hum_SRR332913.sam -o $DIR/India-Hum_SRR332913.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/India-
Hum_SRR332914.sam -o $DIR/India-Hum_SRR332914.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/India-
Hum_SRR332915.sam -o $DIR/India-Hum_SRR332915.bam 
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# Third step: filtering human DNA 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/India13_filtered_R#.fastq --no-aligned 
$DIR/India-Hum_SRR332913.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/India14_filtered_R#.fastq --no-aligned 
$DIR/India-Hum_SRR332914.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/India15_filtered_R#.fastq --no-aligned 
$DIR/India-Hum_SRR332915.bam 
 
# Fourth step: align with vivax reference genome the read unaligned with human genome 
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/PlasmoDB-35_PvivaxP01_Genome.fasta 
$DIR/vivax-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/India13_filtered_R_1.fastq -2 $DIR/India13_filtered_R_2.fastq -S 
$DIR/India13_filt.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/India14_filtered_R_1.fastq -2 $DIR/India14_filtered_R_2.fastq -S 
$DIR/India14_filt.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/India15_filtered_R_1.fastq -2 $DIR/India15_filtered_R_2.fastq -S 
$DIR/India15_filt.sam 
 
# Fifth step: generate filtered bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/India13_filt.sam -o $DIR/India13_filt.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/India14_filt.sam -o $DIR/India14_filt.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/India15_filt.sam -o $DIR/India15_filt.bam 
 
# Sixth step: extract reads mapping with vivax reference genome 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/India13-vivax_R#.fastq --no-unaligned 
$DIR/India13_filt.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/India14-vivax_R#.fastq --no-unaligned 
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$DIR/India14_filt.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/India15-vivax_R#.fastq --no-unaligned 
$DIR/India15_filt.bam 
 
# Seventh step: align again with vivax reference genome  
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/PlasmoDB-35_PvivaxP01_Genome.fasta 
$DIR/vivax-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/India13-vivax_R_1.fastq 
-2 $DIR/India13-vivax_R_2.fastq -S $DIR/India13.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/India14-vivax_R_1.fastq 
-2 $DIR/India14-vivax_R_2.fastq -S $DIR/India14.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/India15-vivax_R_1.fastq 
-2 $DIR/India15-vivax_R_2.fastq -S $DIR/India15.sam 
 
# Eighth step: generate filtered bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/India13.sam -o $DIR/India13.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/India14.sam -o $DIR/India14.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/India15.sam -o $DIR/India15.bam 
 
# Ninth step: Sort the bam files 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/India13.bam $DIR/India13_sorted 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/India14.bam $DIR/India14_sorted 










Annex 14: Script used to filter contamination from Brazil sequences, align with vivax reference 
genome and variant calling 
 
#PBS -N Aligment_2_Variants 
#PBS -q UCTlong 
#PBS -l nodes=1:ppn=32:series600 
DIR=/researchdata/fhgfs/djmmou001/Vivax_data 
 
# NB, PLEASE READ THIS! 
# There is a 2:1 correspondence between RAM and cores on the 600 series. 
# You need to know how much RAM your job will consume before submitting it. 
# Please set the ppn value above to be 1/2 the GB of RAM required.  For 
# example a job needing 10GB of RAM should have ppn=5 
 
# Please leave the hostname command here for troubleshooting purposes hostname 
 
# Your science stuff goes here: 
# First step: alignment with human reference genome 
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/entry.fasta $DIR/Human-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332567_1.fastq.gz 
-2 $DIR/SRR332567_2.fastq.gz -S $DIR/Brazil-Hum_SRR332567.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR332569_1.fastq.gz 
-2 $DIR/SRR332569_2.fastq.gz -S $DIR/ Brazil-Hum_SRR332569.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/Human-ref -1 $DIR/SRR340134_1.fastq.gz 
-2 $DIR/ SRR340134_2.fastq.gz -S $DIR/ Brazil-Hum_ SRR340134.sam 
 
# Second step: generate bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/ Brazil-
Hum_SRR332567.sam -o $DIR/ Brazil-Hum_SRR332567.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/ Brazil-
Hum_SRR332569.sam -o $DIR/ Brazil-Hum_SRR332569.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/entry.fasta $DIR/ Brazil-
Hum_SRR340134.sam -o $DIR/ Brazil-Hum_ SRR340134.bam 
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# Third step: filtering human DNA 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Brazil67_filtered_R#.fastq --no-aligned 
$DIR/Brazil-Hum_SRR332567.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Brazil69_filtered_R#.fastq --no-aligned 
$DIR/Brazil-Hum_SRR332569.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Brazil34_filtered_R#.fastq --no-aligned 
$DIR/Brazil-Hum_SRR340134.bam 
 
# Fourth step: align with vivax reference genome the read unaligned with human genome 
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/PlasmoDB-35_PvivaxP01_Genome.fasta 
$DIR/vivax-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Brazil67_filtered_R_1.fastq -2 $DIR/Brazil67_filtered_R_2.fastq -S 
$DIR/Brazil67_filt.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Brazil69_filtered_R_1.fastq -2 $DIR/Brazil69_filtered_R_2.fastq -S 
$DIR/Brazil69_filt.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 
$DIR/Brazil34_filtered_R_1.fastq -2 $DIR/Brazil34_filtered_R_2.fastq -S 
$DIR/Brazil34_filt.sam 
 
# Fifth step: generate filtered bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Brazil67_filt.sam -o $DIR/Brazil67_filt.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Brazil69_filt.sam -o $DIR/Brazil69_filt.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Brazil34_filt.sam -o $DIR/Brazil34_filt.bam 
 
# Sixth step: extract reads mapping with vivax reference genome 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Brazil67-vivax_R#.fastq --no-unaligned 
$DIR/Brazil67_filt.bam 
/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Brazil69-vivax_R#.fastq --no-unaligned 
$DIR/Brazil69_filt.bam 
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/opt/exp_soft/bam2fastq/bam2fastq -o $DIR/Brazil34-vivax_R#.fastq --no-unaligned 
$DIR/Brazil34_filt.bam 
 
# Seventh step: align again with vivax reference genome  
/opt/exp_soft/bowtie2-2.2.6/bowtie2-build $DIR/PlasmoDB-35_PvivaxP01_Genome.fasta 
$DIR/vivax-ref 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Brazil67-
vivax_R_1.fastq -2 $DIR/Brazil67-vivax_R_2.fastq -S $DIR/Brazil67.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Brazil69-
vivax_R_1.fastq -2 $DIR/Brazil69-vivax_R_2.fastq -S $DIR/Brazil69.sam 
/opt/exp_soft/bowtie2-2.2.6/bowtie2 -p 4 -x $DIR/vivax-ref -1 $DIR/Brazil34-
vivax_R_1.fastq -2 $DIR/Brazil34-vivax_R_2.fastq -S $DIR/Brazil34.sam 
 
# Eighth step: generate filtered bam files 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Brazil67.sam -o $DIR/Brazil67.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Brazil69.sam -o $DIR/Brazil69.bam 
/opt/exp_soft/samtools-0.1.19/samtools view -bT $DIR/PlasmoDB-
35_PvivaxP01_Genome.fasta $DIR/Brazil34.sam -o $DIR/Brazil34.bam 
 
# Ninth step: Sort the bam files 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Brazil67.bam $DIR/Brazil67_sorted 
/opt/exp_soft/samtools-0.1.19/samtools sort $DIR/Brazil69.bam $DIR/Brazil69_sorted 










Annex 15: Script used to generate common vcf file and extract the overlapping position and 




# Generate the common vcf file 
# Index the bam files 
samtools index Anefis.bam  
samtools index Brazil34.bam  
samtools index Brazil67.bam  
samtools index Brazil69.bam  
samtools index India13.bam  
samtools index India14.bam  
samtools index India15.bam  
samtools index Kidal1.bam  
samtools index Kidal2.bam  
samtools index Kidal3.bam  
samtools index Kidal4.bam  
samtools index Madagascar16.bam  
samtools index Madagascar31.bam  
samtools index Madagascar51.bam  
samtools index Maurit08.bam  
samtools index Maurit09.bam  
samtools index Maurit10.bam  
samtools index Maurit11.bam  
samtools index Maurit12.bam  
samtools index Maurit13.bam  
samtools index Maurit14.bam  
samtools index Maurit15.bam  
samtools index Peru02.bam  
samtools index Peru06.bam  
samtools index Peru14.bam  
samtools index Peru16.bam  
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samtools index Peru24.bam  
samtools index TinEssako.bam  
 
# Generate vcf file 
samtools mpileup -u -f PlasmoDB-35_PvivaxP01_Genome.fasta Anefis.bam Brazil34.bam 
Brazil67.bam Brazil69.bam India13.bam India14.bam India15.bam Kidal1.bam Kidal2.bam 
Kidal3.bam Kidal4.bam Madagascar16.bam Madagascar31.bam Madagascar51.bam 
Maurit08.bam Maurit09.bam Maurit10.bam Maurit11.bam Maurit12.bam Maurit13.bam 
Maurit14.bam Maurit15.bam Peru02.bam Peru06.bam Peru14.bam Peru16.bam Peru24.bam 
TinEssako.bam > All_vivax.bcf 
 
bcftools view -v -c -g All_vivax.bcf > All_vivax.vcf 
 
# Extract the overlapping position 
bcftools query -f '%CHROM\t%POS\t%POS\n' TinEssako.vcf > TinEssako_positions.csv 
bcftools view --targets-file TinEssako_positions.csv All_vivax.vcf > All_vivax_Overlap.vcf 
 
# Generate the ped file 
/home/moussa/Downloads/plink --vcf All_vivax_Overlap.vcf --snps-only --biallelic-only 






















Annex 16: Script used to convert ped to fasta file 
 
# PED to FASTA converter, ped2fasta.pl 
# Gets first 6 columns of each line as header line and the rest as 
# the sequence replacing 0s with Ns and organizes it into a FASTA file 
 
# Note 0s are for missing nucleotides defined by default in PLINK 
 
# How to run: perl ped2fasta.pl "C:\path\to\PED_File" 
 
use strict; 
my $file = $ARGV[0]; # Path to PED file 
my @columns; 
my $sequence; 
open(my $inf, "<", $file.".ped") or die $!; 
open(my $ouf, ">", $file.".fa") or die $!; 
while (my $row = <$inf>) { 
 # Each row belongs to one individual 
 chomp $row; 
 @columns = split(" ", $row); # Splits columns of each line into an array 
 print $ouf ">", join(" ", @columns[0..5]), "\n"; # Joins and prints first 6 columns of 
each line 
 $sequence = join("", @columns[6..$#columns]); # Joins all nucleotides 
 $sequence =~ s/0/N/g; # Replaces 0s with Ns 











Annex 17: Script used to align sequences for evolutionary relationship analysis purpose 
 
#!/bin/bash 
#PBS -l select=2:ncpus=24 
#PBS -l walltime=120:00:00 
#PBS -P CBBI0818 
#PBS -q normal 
#PBS -o /mnt/lustre/users/mdjimde/moussa_data/stdout.txt 
#PBS -e /mnt/lustre/users/mdjimde/moussa_data/stderr.txt 
#PBS -N Align_Taxa 
#PBS -M mdjimde@icermali.org 
#PBS -m be 
 
module add chpc/BIOMODULES 
module add mafft/7.305_intel16.0.1 
 



















Annex 18: Standard Operating Procedure (SOP) used for DNA extraction from RDTs 
 
a- Materials and Equipment 
- QiaAmp DNA Blood Midi Kit (100) including: 
o Qiagen Protease 
o Buffer AL (lysis buffer) 
o Buffer ATL (tissue lysis buffer) 
o QiaAmp Midi columns with collection tubes 
o Buffer AW1 (wash buffer 1) 
o Buffer AW2 (wash buffer 2) 
o Buffer AE 
o Collection tubes for eluted DNA 
- Centrifuge with swinging bucket rotor and 15mL tube holders 
- 70C water bath with floatation device 
- Ethanol (96-100%) 
- Proteinase K 
- 2mL centrifuge tubes and tube racks 
- 1.5mL microcentrifuge tubes and racks 
- 5mL serological pipets and pipet pump 
- 1000µL filter tips and P-1000 pipettor 
- Pipet sheaths 
- Pliers to break the RDTs 
- Scissors to cut the strip 
- Distilled water 
 
b- Procedure 
- The RDTs have been broken to extract the strip on which the drop of blood has migrated. 
- The dried blood spot on the the strip were placed into a 1.5 ml microcentrifuge tube. 
- Reconstitute Qiagen Protease (if not already done). 
- Tissue lysis buffer (180 µl of Buffer ATL) was added in the tube. We then left the tube 
in incubation overnight at room temperature (15–25°C).  
- The next day, the tube where briefly centrifuged after 10 minutes’ incubation at 85°C 
to remove drop from lib.  
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- Proteinase K (20 µl) was added. The mix was vortexed and incubated at 56°C during 1 
hour following by brief centrifuge.  
- Then, lysis buffer (200 µl Buffer AL) was added and thoroughly vortex for mix and 
incubated during 10 minutes at 70°C and briefly centrifuged. 
- 200 µl of 96-100% ethanol was added and mixed thoroughly using vortex following by 
a brief centrifuge. 
- After applied from the microcentrifuge tubes to the QIAamp Mini spin column, the 
mixtures were centrifuged at 8000 rpm for 1 minute. 
- After centrifugation, QIAamp Mini spin column was placed in 2 ml collection tubes. 
The filtrate was discarded. 
- 500 µl of Buffer AW1 was added carefully (without wetting the rim) to the QIAamp 
Mini spin column and centrifuged at 8000 rpm for 1 minute. 
- QIAamp Mini spin column was placed in 2 ml collection tubes and as previous step the 
filtrate was discarded. 
- 500 µl of Buffer AW2 was added carefully (without wetting the rim) to the QIAamp 
Mini spin column and centrifuged at full speed 14,000 rpm for 3 minutes. 
- QIAamp Mini spin column was placed in new 2 ml collection tubes and centrifuged at 
full speed for 1 minute. 
- The QIAamp Mini spin column was finally placed in new 1.5 ml microcentrifuge tubes. 
- The tubes containing the filtrate was discarded. 
- The tubes were carefully opened and 100 µl distilled water was added. 
- The tube was incubated at room temperature (15–25°C) for a minute before 
centrifugation. The speed used was 8000 rpm for 1 minute. 
 
c- Limitations of the Procedure 
The QiaAmp DNA Blood Midi Kit is more expensive than the Nucleon DNA Extraction Kit; 









Annex 19: SOP used for Nested Polymerase Chain Reaction (PCR) 
 
a- Materials and Equipment 
- Thermocycler 
- Centrifuge 
- PCR Buffer (+ MgCl2) 
- 10xdNTPs 
- Taq polymerase 
- Water for PCR 
- Bovine Serum Albumin (BSA) 
- NEB Digestion Buffer 
- ApoI Digestion Enzyme 
- Sterile Gloves 
- Tubes (1.5ml, 0.5ml, 0.2ml) and racks 
- DNA 
- pipettes and tips (1000µl, 200µl, 20µl and 10µl) 
- Markers 
- Water bath or incubator 
- Primers for species diagnostic: 
Plasmodium species Primers 
Plasmodium sp. rPLU5: CCT GTT GTT GCC TTA AAC TTC 
rPLU6: TTA AAA TTG TTG CAG TTA AAA G 
P. falciparum rFAL1: TTA AAC TGG TTT GGG AAA ACC AAA TAT ATT  
rFAL2: ACA CAA TGA ACT CAA TCA TGA CTA CCC GTC 
P. malariae rMAL1: ATA ACA TAG TTG TAC GTT AAG AAT AAC CGC 
rMAL2: AAA ATT CCC ATG CAT AAA AAA TTA TAC AAA 
P. vivax rVIV1: CGC TTC TAG CTT AAT CCA CAT AAC TGA TAC  
rVIV2: ACT TCC AAG CCG AAG CAA AGA AAG TCC TTA 
P. ovale curtisi rOVA1: ATC TCT TTT GCT ATT TTT TAG TAT TGG AGA 





- Preparation of the reaction mixture 
Reagents Initial concentration Final concentration Volume (µL) 
Buffer/MgCl2 5X/17.5 nM 1X/3.5 nM 5 
dNTPs 10X/2nM 1X/200µM 2.5 
Primers 100X/10µM 1X/100nM 0.25 
Taq Polymerase 5U/µL 0.025U 0.125 
PCR water - - 16.125 
Total   24 
 
- First amplification (PCR1) programme: 
o 95°C for 5 min;  
o 94°C for 30sec,  
o 58°C for 30sec,  
o and 72°C for 30sec;  
o 44 cycles go to 2;  
o 72°C for 5 min 
- Second amplification (PCR2) programme: 
o 95°C for 5 min;  
o 94°C for 30sec,  
o 58°C for 30sec,  
o and 72°C for 30sec;  
o 19 cycles go to 2,  













Annex 20: SOP used for Selective Whole Genome Amplification (sWGA) 
 
a- Materials and Equipment 
- Thermocycler 
- Centrifuge 
- Taq polymerase 
- Water for PCR 
- Sterile Gloves 
- Tubes (1.5ml, 0.5ml, 0.2ml) and racks 
- DNA extracted from RDT samples using the QIAamp DNA mini kit (Qiagen, Valencia, 
CA) 
- Phi29 Buffer 
- Phi29 DNA polymerase 
- dNTPs 
- BSA 
- Phi29 polymerase  











o 5'GGTTAGCG*G*C-3'and  
o 5'-AACGAAT*C*G-3' 
b- Procedure 
- Ramp down 35°C, the temperature was increased by 1°C each 10 minutes 
- 16 hours at 30°C 
- 10 minutes at 65°C 
- Hold at 4°C 
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c- DNA quantification 
NanoDrop 2000 UV-vis spectrophotometer (made in U.S.A.) was used to quantify DNA before 
and after sWGA. 
 
